

Global Semiconductor Capital Equipment

Global Semiconductor Equipment: Equip this! Raising WFE growth to 75% in two years



David Dai, CFA
 +852 2918 5704
 david.dai@bernsteinsg.com



Stacy A. Rasgon, Ph.D.
 +1 213 559 5917
 stacy.rasgon@bernsteinsg.com



Qingyuan Lin, Ph.D.
 +852 2123 2654
 qingyuan.lin@bernsteinsg.com



Mark Li
 +852 2123 2645
 mark.li@bernsteinsg.com



Juho Hwang
 +81 3 6777 6980
 juho.hwang@bernsteinsg.com



Carmine Milano, CFA
 +44 20 7762 1857
 carmine.milano@bernsteinsg.com



Alrick Shaw
 +1 917 344 8454
 alrick.shaw@bernsteinsg.com



Arpad von Nemes
 +1 917 344 8461
 arpad.vonnemes@bernsteinsg.com



Eva Zhang
 +1 212 845 7839
 eva.zhang@bernsteinsg.com

We significantly lift our 2026 WFE to \$148bn (+26.3% YoY) from 141bn (+21.4%), 2027 WFE to \$204bn (+32.6% YoY) from \$175bn (+18.2%), and 2028 WFE to \$259bn (+27% YoY) from \$198bn (+13%), based on outlook on a broad-based increase in investment, both in terms of applications and geography. The two-year growth of 75% strengthens our WFE upcycle call. The uplift is across all applications, but slightly more from non-China memory, and China foundry / logic. By application, we now forecast to DRAM WFE to grow 53%/37%, NAND 58%/42%, Logic/Foundry 20%/19% in 2027/28, respectively. Our latest forecast can be downloaded here: [Bernstein WFE model](#).

We now forecast global ex-China WFE to grow 36% in 2026 and 37% in 2027. We revise up our 2026 ex-China WFE by \$7bn, of which the largest delta is \$3.4bn in foundry, followed by \$2.6bn in DRAM. For 2027, we revise up by \$22.8bn to now see +37% (prior +25%) growth. DRAM comprises \$10.7bn of the revision, followed by \$9.8bn from foundry / logic. For 2028, we revise up our ex-China WFE estimates by \$36.8bn to now see +27% (+13% prior) growth, for which the revision is also driven by DRAM (\$18bn) as well as foundry / logic (\$15bn).

We are now forecasting China WFE demand to reach \$57/\$73/\$101bn in 2026-28.

We lower down 2026 number by \$1.1bn but significantly revised up that for 2027-28 by \$6.3/\$24.0bn. In 2026, the number is mainly dragged down by weak imports due to DUV shortage, while domestic players are expected to deliver 41% YoY growth and reach \$16 billion. Beyond 2026, we are expecting significant capacity expansion among all sectors in China, including memory, advanced logic, and matured logic. Memory is still expected to lead the surge with +88%/+81%/+62% YoY growth rates in 2026-28. The rationale for advanced logic's explosion mainly comes from the Huawei's Tau (τ) Scaling Law introduction, which use advanced packaging to stack multiple dies to deliver better performance and consumes more wafers. As for matured logic, local NAND vendor outsourcing CMOS production to foundry, AI driven new demand, and industrial/auto upcycle creates a new round of tight supply on matured node, urging foundries to resume aggressive capacity expansion.

We adjust our US Semicap (LRCX, KLAC, and AMAT) models upward to align with our new WFE updates and take target prices up for all three with increasing conviction that the current upcycle in equipment spending has legs. We note that we had already partially increased our LRCX and KLAC numbers at their earnings a couple of weeks ago, hence our AMAT adjustments today are larger than for the other two (AMAT reports earnings this week on Thursday). We like all three of our names, though probably ordering in preference AMAT first (most exposure to leading edge logic, DRAM, and packaging, and a bit cheaper) followed by LRCX (more expensive but great execution and NAND upgrade exposure) followed by KLAC (growing a bit slower than the others this year given longer leadtimes but with the most leading edge logic and a high likelihood of a strong 2027+ as those longer leadtimes meet oncoming cleanroom space). We raise our LRCX price target to \$385 (vs \$365 prior) and KLAC to \$250 (vs \$225 prior) and AMAT to \$675 (vs \$525 prior). All three stocks - Outperform.

For Japan semi, we continue to prefer Kokusai (OP) and Tokyo Electron (OP) to benefit from the stronger memory capex. As we revise up more memory WFE relative to logic / foundry, we continue to prefer companies with more memory exposure in our coverage, in the order Kokusai > TEL > Screen. As for China, we expect that Kokusai's exposure will not get eroded by localization in the near term; instead it will benefit from the capacity ramp up. TEL/Screen both faced share loss in China last year, but we expect them to still find growth there going forward.

For EU Semis, ASML stands out as our top pick. We expect topline in \$ to grow at a 34% CAGR25–28E, driven by a materially improving outlook, supported by rising capex in adv. logic and especially in DRAM, as well as higher litho intensity. We expect strong growth for both EUV and DUV tools, in line with company capacity expansion. While we forecast declining China revenue in line with guidance at 20% of total sales, we see considerable potential upside driven by continued strength in China's demand for DUV systems.

For Chinese semicap, we maintain Outperform on AMEC, NAURA and Piotech. Our channel check on DRAM/NAND/Adv logic/matured logic capacity expansion are still higher than companies' guidance, indicate potential upward revision on order. Recent correction creates an attractive entry point to wait for 2H26 rebound.

BERNSTEIN TICKER TABLE

Ticker	Rating	Cur	10 Aug 2026	Price Target	TTM	Reported EPS				Reported P/E (x)		
			Closing Price		Rel. Perf.	Cur	2025A	2026E	2027E	2025A	2026E	2027E
8035.JP (Tokyo Electron)	O	JPY	56,750	79,300	129.8%	JPY	1,250.88	1,687.17	2,635.81	45.4	33.6	21.5
7735.JP (Screen)	M	JPY	13,175	15,000	81.9%	JPY	486.61	574.49	759.55	27.1	22.9	17.3
6525.JP (Kokusai)	O	JPY	8,006.00	12,420	123.9%	JPY	128.63	262.29	373.69	62.2	30.5	21.4
6920.JP (Lasertec)	O	JPY	39,590	54,000	137.2%	JPY	863.65	1,185.31	1,348.53	45.8	33.4	29.4
6146.JP (DISCO)	O	JPY	62,980	99,000	18.5%	JPY	1,245.79	1,830.28	2,336.94	50.6	34.4	26.9
6857.JP (Advantest)	O	JPY	34,260	45,800	190.0%	JPY	513.30	948.96	1,088.87	66.7	36.1	31.5
AMAT (Applied Materials)	O	USD	539.14	675.00	169.3%	USD	9.42	12.17	16.68	57.3	44.3	32.3
OLD				525.00					15.56			
LRCX (Lam Research)	O	USD	311.35	385.00	183.6%	USD	5.82	9.22	10.97	53.5	33.8	28.4
OLD				360.00					9.17		10.14	
KLAC	O	USD	198.11	250.00	94.2%	USD	3.76	5.47	7.05	52.7	36.2	28.1
OLD				225.00					6.52			
002371.CH (NAURA)	O	CNY	760.00	680.00	100.3%	CNY	5.66	10.22	16.41	134.2	74.4	46.3
688012.CH (AMEC)	O	CNY	389.99	335.57	165.9%	CNY	2.28	3.32	4.82	170.9	117.5	80.9
OLD				500.00					4.95		7.18	
688072.CH (Piotech)	O	CNY	728.00	580.00	311.5%	CNY	3.32	8.12	12.40	219.3	89.6	58.7
ASML.NA (ASML)	O	EUR	1,499.00	2,500.00	129.7%	EUR	24.72	38.91	53.56	60.7	38.5	28.0
ASML (ASML)	O	USD	1,740.99	2,859.00	118.7%	USD	27.95	44.01	60.58	53.9	34.2	24.9
JPL			2,643.59									
SPX			7,757.64									
ASIAx			1,914.02									
EDME			1,638.96									

PRICE TARGET CHANGE / ESTIMATE CHANGE IN BOLD

O - Outperform, M - Market-Perform, U - Underperform, NR - Not Rated, CS - Coverage Suspended

AMAT, LRCX, KLAC estimate is Adjusted EPS; AMAT, LRCX, KLAC valuation is Adjusted P/E (x); 6920.JP, LRCX, KLAC base year is 2026;

Source: Bloomberg, Bernstein estimates and analysis.

INVESTMENT IMPLICATIONS

Tokyo Electron: Outperform, PT=¥79,300. TEL is the #4 SPE supplier globally and the biggest Japanese SPE supplier with major presence in 6 product segments. It is expected to gain share and expand margins with competitive pricing after yen depreciation.

ASML: Outperform, PT: EUR 2,500.00. We expect ASML to deliver solid growth over the next five years, supported by rising capex in DRAM and advanced logic. We value ASML using a target PE of 40x, and applying it to our Q5–8 EPS of EUR 62.6 translates in our TP at EUR 2,500. We reiterate our Outperform rating and top pick. For ASML's U.S. listing, we convert this using the EUR/USD exchange rate, which yields a price target of **USD 2,859.00**.

Kokusai: Outperform, PT=¥12,420. Kokusai is the leader in batch ALD (atomic level deposition), which should see more adoption in advanced nodes especially GAA (gate-all-around). The biggest use of batch ALD is in NAND, for which we are seeing positive signs.

Screen: Market-Perform, PT=¥15,000. Leading supplier in cleaning equipment with the lowest valuation in our coverage, but also the one with the least specific growth drivers. Cleaning intensity is not increasing, and the market is competitive with both global rivals (TEL, Lam) and Chinese (ACMR, Naura). Declining China revenue contribution presents margin downside risk. Potential upside from panel level packaging is worth watching.

Lasertec: Outperform, PT=¥54,000. As major supplier for mask inspection (~50% share) and sole supplier for actinic inspection, Lasertec delivered phenomenal growth in the past. We anticipate the revenue growth to reaccelerate as ACTIS 200 HiT enters the market and see more wafer fab adoption. KLA's potential launch of actinic inspection presents a major threat.

AMAT (Outperform, \$675.00): We maintain a positive view on secular WFE growth and see a number of drivers for AMAT including SAM growth, an increasing services narrative, and capital return.

LRCX (Outperform, \$385.00): The company is benefiting from key inflections (GAA, packaging, HBM, NAND upgrades) and CY26/27 commentary seems supportive.

KLAC (Outperform, \$250.00): Amid positive WFE trends KLAC possesses structural growth drivers, a strong and durable competitive position, lower China replacement risk, and disciplined capital allocation, warranting premium valuation.

NAURA (Outperform, CNY 680.00): As the domestic WFE leader, NAURA has the broadest product portfolio covering Deposition (PVD, CVD), Dry Etch (ICP), Thermo Processes, and Cleaning, as well as a more diverse client base covering leading logic, DRAM, NAND players, benefiting from the WFE domestic substitution in China with acceleration share gain.

AMEC (Outperform, CNY 335.57): Primarily focus on Dry Etch (CCP, ICP) with rapid expansion in Deposition (ALD, LPCVD, EPI), commonly perceived as the domestic WFE company with the best technology and widest global recognition, continue to benefit from the WFE domestic substitution in China with acceleration share gain. The company completed their Annual Equity Distribution in May 2026, the plan grants 4.9 bonus shares per 10 shares together with a cash dividend of RMB 3.50 (tax inclusive) per 10 shares, increasing its total shares outstanding by 49%. As a result, our forecast EPS has been accordingly adjusted downward on a per-share basis, and our PT has been revised accordingly. There is no change to our net income projections or valuation multiple. The PT adjustment is therefore purely mechanical and does not imply any change in our earnings outlook or investment thesis.


Piotech (Outperform, CNY 580.00): Rising domestic WFE vendor primarily focus on Deposition (PECVD, HDPCVD, SACVD, ALD) with expansion in W2W and C2W hybrid bonding equipment for advanced packaging. Piotech has a strong track record of product innovation, which will allow it to benefit from the WFE domestic substitution in China with acceleration share gain.

DETAILS

We lift our WFE forecast for CY2027 to \$204bn (\$175bn prior) and CY2028 to \$259bn (\$198bn prior)


- **For CY27**, we now forecast **\$204bn WFE** spending (\$175bn prior) with growth to **+33% YoY** (+18% prior). The revision is mainly to reflect our improved outlook on DRAM as well as logic / foundry. Geographically, we lift our 2027 China WFE by \$6.3bn, and ex-China WFE by \$22.8bn.
- **DRAM/NAND**: We raise our memory WFE capex to \$89bn (\$75bn prior) and DRAM WFE capex to \$69bn (prior \$57bn) in 2027 (Exhibit 6). This reflects our view of accelerated spending mainly from ex-China but also China DRAM makers.
- **Logic/Foundry**: We keep our logic / foundry WFE capex largely unchanged at \$89bn (Exhibit 7), and see +8% YoY (+7% prior). Incrementally, we mainly expect a slightly higher logic IDM spending from Intel. China estimates are unchanged.
- **China**: given our channel checks on domestic Advanced Logic/Matured Logic/Memory CapEx expansion plan, we further revise up our 2027 number by \$6.3bn. China's WFE demand continue to beat the market projection.
- **For CY28**, we now forecast **\$259bn WFE** spending (\$198bn prior) with growth of +27% (+13% prior). The revision from equally from logic / foundry (up \$31bn) as memory (up \$30bn). Within memory, we raise DRAM by \$24bn and NAND by \$6bn. By region, we revise up ex-China by \$37bn and China by \$24bn.
- **For CY26**, we lift the WFE growth estimate to +26% YoY (+21% prior) which is largely in line with the range of the latest commentary from the major semicap suppliers (**Exhibit 1-Exhibit 5**), and now forecast \$154bn (\$148bn prior) WFE spending. The upward revision is mainly based on a stronger outlook on ex-China foundry / DRAM. Geographically, we lift ex-China estimates by \$7bn, offset by a cut of \$1.1bn in China.
- **China**: We lower down our forecast of China WFE by **\$1.1bn** for CY26 due to our conservative view for the full year import (mainly dragged by Litho shortage). Although the number looks less exciting, we remain confident that the import will recover in 2H26 and bring the full year import to a new record high of \$41bn. Meanwhile, with higher visibility on domestic players' new order guidance from 2025 onward, we further raise up domestic vendors' revenue to \$16bn, indicating a 41% YoY growth. All together, we forecast China WFE market to keep growing, mainly driven by strong performance of domestic vendors.
- **Guidance from major semicap companies on CY26 now suggest that their China revenue will be flattish vs CY25.** The tones were better than previous quarters where they indicate China revenue will be down, and we expect the global companies to further revise that up in the next few quarters. Stronger order growth from local players will be reflected in CY27 spending due to 1-year of lead time from order to revenue recognition.

EXHIBIT 1: We revise up our WFE projection for CY26-CY28 to reflect our latest views...




Source: Gartner, SEMI, Bernstein estimates and analysis.

EXHIBIT 3: In China, we now see +28% / +38% YoY (+15% / +16% prior) in 2027 / 2028.




Source: Gartner, SEMI, Bernstein estimates and analysis.

EXHIBIT 2: ...and we now model +33% (+18% prior) growth in CY27, +27% (+13% prior) in CY28.



Source: Gartner, SEMI, Bernstein estimates and analysis.

EXHIBIT 4: We lift our 2027/2028 ex-China WFE to +37% / +22% YoY (+21% / +12% prior).



Source: Gartner, SEMI, Bernstein estimates and analysis.


EXHIBIT 5: **Our WFE forecast of +26% YoY (or \$154bn) for CY2026 is largely in line with the latest forecasts by major semicap companies.**

Company Name	Ticker	CY2025 WFE	CY2026 WFE	CY2027 WFE
Tokyo Electron	8035.JP	~120	>150	>190
Lam Research	LRCX.US	close to 110	low 150s	Extraordinary setup for WFE growth
KLA	KLAC.US	low 120s	low 150s	>190
Screen	7735.JP	117	>140	Similar level of growth
Kokusai	6525.JP	5% YoY	+25% YoY	+20% YoY

Tokyo Electron, Screen and Kokusai are covered by Bernstein Japan Semiconductor Team. Lam Research and KLA are covered by Bernstein US Semiconductor Team.


Source: Company disclosures, Bernstein analysis.

EXHIBIT 6: **We now estimate 2027/2028 WFE spending for DRAM to be \$69bn / \$96bn (\$57bn / \$71bn prior), NAND \$20bn / \$29bn (\$18bn / \$23bn prior), respectively...**



Source: Gartner, SEMI, Bernstein estimates and analysis.

EXHIBIT 7: **...and for Logic/Foundry, we now see 2027/2028 WFE of \$104bn/\$124bn (\$89bn/\$93bn prior).**



Source: Gartner, SEMI, Bernstein estimates and analysis.

EXHIBIT 8: All five companies expect China WFE to be roughly flat YoY but China as a percentage of revenue to normalize lower in 2026 vs. the elevated 2024–2025 levels

Company	Ticker	Lastest Comments on China WFE (CY3Q26 & CY2026)
ASML	ASML.NV	ASML guided China to represent approximately 20% of total net sales in 2026 , consistent with its current system backlog — a significant decline from 33% in 2025 and 41% in 2024. Management views the elevated 2024–2025 China sales levels as unsustainable, reflecting a normalization after fulfilling a substantial backlog.
Applied Materials	AMAT	In Q2 FY2026, China accounted for 24% of semiconductor systems plus AGS revenue , down from 30% of overall sales in Q1 FY2026, where revenue declined 7% year-over-year. For the full calendar year, Applied Materials expects its China business, along with its ICAPS business worldwide, to be flat to slightly higher — an improvement from the prior guidance of down year-over-year. Management expects China to be flat to slightly up for the calendar year, with ICAPS globally also guided to be flattish.
Lam Research	LRCX	China accounted for 26% of total revenue in Q4 FY2026 , further decreased from 34% in Q3 FY2026, also the lowest quarter in absolute terms in FY2026. Lam explained that revenues from global multinational customers with fabs in China increased while revenues from indigenous Chinese customers declined, and it anticipates that similar trend will hold in the later part of the year .
KLA	KLAC	China represented 26% of total revenue in Q4 FY2026 , up from approximately 24% in Q3 FY2026, with minimal impact expected from additional US export bans. For FY2026, KLA's revenue from China accounted ~30% of its total revenue .
Tokyo Electron	8035.JP	In Q1 FY2027, China represented 30.4% of total sales , increasing 3.6 percentage point QoQ. On FY2027 full-year basis, proportion of sales in China is expected to be in the low 30s percentage level .

Source: Company reports, Bernstein analysis

We adjust our US Semicap (LRCX, KLAC, and AMAT) models upward to align with our new WFE updates and take target prices up for all three with increasing conviction that the current upcycle in equipment spending has legs. We like all three of our names, though probably ordering in preference AMAT first (most exposure to leading edge logic, DRAM, and packaging, and a bit cheaper) followed by LRCX (more expensive but great execution and NAND upgrade exposure) followed by KLAC (growing a bit slower than the others this year given longer leadtimes but with the most leading edge logic and a high likelihood of a strong 2027+ as those longer leadtimes meet oncoming cleanroom space). We raise our LRCX price target to \$385 (vs \$365 prior) and KLAC to \$250 (vs \$225 prior), and AMAT to \$675 (vs \$525 prior). We rate all three stocks Outperform.

- **We adjust our AMAT, LRCX and KLAC models upward to align with our WFE updates**, taking up numbers and target prices. We note that we had already partially increased our LRCX and KLAC numbers at their earnings a couple of weeks ago, hence our AMAT adjustments today are larger than for the other two (AMAT reports earnings this week on Thursday). A comparison of our new estimates vs old for AMAT, LRCX and KLAC can be found in **Exhibit 9**.
- While valuations remain somewhat elevated in the space (**Exhibit 12-Exhibit 16**) the recent pullback has softened them somewhat, and we increasingly gaining conviction that the current WFE spending upcycle has legs.
- We like all three of our names, though probably ordering in preference AMAT first (most exposure to leading edge logic, DRAM, and packaging, and a bit cheaper) followed by LRCX (more expensive but great execution and NAND upgrade exposure) followed by KLAC (growing a bit slower than the others this year given longer leadtimes but with the most leading edge logic and a high likelihood of a potentially strong 2027+ as those longer leadtimes meet oncoming cleanroom space).
- We raise our AMAT price target to \$675 (vs \$525 prior), LRCX price target to \$385 (vs \$360 prior) and KLAC to \$250 (vs \$225 prior).
- We remain Outperform on all three stocks.


EXHIBIT 9: **AMAT, LRCX and KLAC Bernstein estimates vs prior**

AMAT	FY2026E			FY2027E			FY2028E		
	Bernstein	Old	Chg	Bernstein	Old	Chg	Bernstein	Old	Chg
Revenue	\$33,233	\$33,233	0%	\$42,628	\$40,688	5%	\$53,053	\$46,646	14%
YoY	17.1%	17.1%		28.3%	22.4%		24.5%	14.6%	
Gross Margin	49.9%	49.9%	0%	50.5%	50.5%	0%	50.9%	50.9%	0%
Operating Margin	32.5%	32.5%	0%	34.9%	34.1%	2%	36.5%	35.3%	4%
EPS	\$12.17	\$12.17	0%	\$16.68	\$15.56	7%	\$22.04	\$18.69	18%
YoY	29.2%	29.2%		37.1%	27.9%		32.1%	20.1%	

LRCX	FY2027E			FY2028E			FY2029E		
	Bernstein	Old	Chg	Bernstein	Old	Chg	Bernstein	Old	Chg
Revenue	\$34,554	\$34,346	1%	\$38,871	\$36,274	7%	\$45,288	\$42,693	6%
YoY	48.7%	47.8%		12.5%	5.6%		16.5%	17.7%	
Gross Margin	51.6%	51.6%	0%	52.5%	52.5%	0%	53.4%	53.4%	0%
Operating Margin	39.1%	39.1%	0%	40.3%	39.9%	1%	42.0%	41.7%	1%
EPS	\$9.22	\$9.17	1%	\$10.97	\$10.14	8%	\$13.65	\$12.78	7%
YoY	58.5%	57.6%		18.9%	10.7%		24.5%	26.0%	


KLAC	FY2027E			FY2028E			FY2029E		
	Bernstein	Old	Chg	Bernstein	Old	Chg	Bernstein	Old	Chg
Revenue	\$18,049	\$18,049	0%	\$22,173	\$20,787	7%	\$25,038	\$22,408	12%
YoY	32.9%	32.9%		22.8%	15.2%		12.9%	7.8%	
Gross Margin	62.5%	62.5%	0%	63.1%	63.1%	0%	63.5%	63.5%	0%
Operating Margin	46.6%	46.6%	0%	47.7%	47.2%	1%	48.3%	47.5%	2%
EPS	\$5.47	\$5.47	0%	\$7.05	\$6.52	8%	\$8.26	\$7.25	14%
YoY	45.6%	45.6%		28.8%	19.2%		17.1%	11.1%	

Source: Bernstein estimates and analysis

EXHIBIT 10: **AMAT trades at ~33x forward earnings...**


Bloomberg data as of 8/7/2026.

Source: Bloomberg, Bernstein analysis

EXHIBIT 11: **...a ~35% premium to the SOX and a ~57% premium to the SPX**


Bloomberg data as of 8/7/2026.

Source: Bloomberg, Bernstein analysis

EXHIBIT 12: **LRCX trades at ~33x...**


Bloomberg data as of 8/7/2026.

Source: Bloomberg, Bernstein analysis

EXHIBIT 14: **KLAC trades at ~36x P/FE...**


Bloomberg data as of 8/7/2026.

Source: Bloomberg, Bernstein analysis

EXHIBIT 13: **...a ~36% premium to the SOX and a ~58% premium to the SPX**

Bloomberg data as of 8/7/2026.

Source: Bloomberg, Bernstein analysis

EXHIBIT 15: **...a 49% premium to the SOX and ~72% premium to the SPX**

Bloomberg data as of 8/7/2026.


Source: Bloomberg, Bernstein analysis

EXHIBIT 16: **AMAT, LRCX and KLAC are amongst the more expensive “big-5” semicap names, although all of them trade in a relatively narrow valuation band**

providing further upside. In addition, we expect DUV to grow at a 23% CAGR over the next three years, as advanced logic and especially DRAM capacity ramp-up requires not only more EUV but also more DUV. For DRAM, we estimate that each EUV machine requires around two ArFi tools. Our estimates are slightly more conservative than ASML's projected capacity expansion of 30% YoY over the next two years. We forecast DUV capacity reaching 200 units by 2028, compared with ASML's target of 220 units. (Exhibit 18).


- While we model China revenue to decline significantly in 2026 following three years of strong sales, in line with company guidance for China to account for 20% of sales, we now expect China demand to remain very strong over the next three years. With China WFE now expected to reach US\$100bn in 2028, supported by expanding advanced logic and DRAM capacity, China litho demand could represent US\$18-20bn of DUV revenue alone, representing a significant upside to our DUV estimates.

EXHIBIT 17: We expect ASML's system sales to accelerate at a rapid pace over the next three years, achieving a 34% CAGR and reaching ~ US\$ 66 Bn by 2028.



Source: Company reports, Bernstein analysis and estimates

EXHIBIT 18: We expected EUV to lead growth with a 44% CAGR, with units more than doubling from 48 in 2025 to 118 in 2028 of which 8 HNA systems.




Source: Company reports, Bernstein analysis and estimates

For Chinese semicap, we maintain Outperform on NAURA, AMEC and Piotech.


- We expect 2026 to be a very strong year driven by AI/Memory/Foundry demand localization, but what the market might still underestimate the demand strength for 2027, where we expect even the growth rate for order will further accelerate compared to 2026, therefore the recent dip will create a good opportunity to add. For the near term, the release of Kirin 2026 chip use logic folding, YMTC prospectus, and the delivery of Huawei superPoD in 2H26 will be positive catalysts to watch out for. Local companies are gradually revising up their 2026 order growth outlook, and we expect further revision to come in remaining months in 2026.
- For the near term, we believe the biggest gap on market expectation is the upside on advanced logic, with about 40% exposure in advanced logic NAURA remain the biggest beneficiary when advanced logic capacity expansion start to accelerate, therefore we believe NAURA could capture the biggest upside, we like NAURA > AMEC > Piotech.

EXHIBIT 19: Jun 2026 WFE import was USD 3,414 mn, YoY +1% & MoM +57%



Source: General Administration of Customs of the People's Republic of China, Bernstein analysis

EXHIBIT 20: Jun 2026 YTD import YoY -10%, mainly due to weak Lithography & Material Removal and Cleaning import



Source: General Administration of Customs of the People's Republic of China, Bernstein analysis

APPENDIX - FINANCIAL FORECASTS

EXHIBIT 21: Bernstein AMAT Income Statement

INCOME STATEMENT																
Fiscal Period	2025	2026E	2027E	2028E	Q125	Q225	Q325	Q425	Q126	Q226	Q326E	Q426E	Q127E	Q227E	Q327E	Q427E
Net Sales	\$28,368	\$33,233	\$42,628	\$53,053	\$7,166	\$7,100	\$7,302	\$6,800	\$7,012	\$7,910	\$8,951	\$9,360	\$9,620	\$10,275	\$10,996	\$11,737
COGS	\$14,533	\$16,655	\$21,118	\$26,073	\$3,663	\$3,609	\$3,733	\$3,528	\$3,570	\$3,957	\$4,466	\$4,661	\$4,781	\$5,096	\$5,443	\$5,798
Non-GAAP Gross Profit	\$13,835	\$16,578	\$21,509	\$26,980	\$3,503	\$3,491	\$3,569	\$3,272	\$3,442	\$3,953	\$4,484	\$4,699	\$4,839	\$5,179	\$5,553	\$5,939
Non-GAAP Operating Expenses	\$5,273	\$5,780	\$6,652	\$7,589	\$1,313	\$1,311	\$1,324	\$1,325	\$1,335	\$1,417	\$1,486	\$1,542	\$1,585	\$1,632	\$1,687	\$1,749
R&D	\$3,570	\$4,203	\$4,940	\$5,609	\$859	\$893	\$901	\$917	\$928	\$1,027	\$1,101	\$1,147	\$1,183	\$1,212	\$1,254	\$1,291
Marketing and Selling	\$858	\$922	\$1,010	\$1,167	\$206	\$216	\$224	\$212	\$222	\$233	\$233	\$234	\$240	\$247	\$253	\$270
General and administrative	\$910	\$683	\$750	\$861	\$256	\$207	\$204	\$243	\$189	\$164	\$161	\$168	\$173	\$185	\$192	\$200
Other	\$181	\$265	\$0	\$0	\$0	\$0	\$0	\$181	\$265	\$0	\$0	\$0	\$0	\$0	\$0	\$0
Non-GAAP adjustment	(\$246)	(\$292)	(\$48)	(\$48)	(\$8)	(\$5)	(\$5)	(\$228)	(\$269)	(\$7)	(\$9)	(\$7)	(\$12)	(\$12)	(\$12)	(\$12)
Non-GAAP Operating Income	\$8,562	\$10,796	\$14,857	\$19,391	\$2,190	\$2,180	\$2,245	\$1,947	\$2,107	\$2,536	\$2,997	\$3,157	\$3,254	\$3,547	\$3,866	\$4,190
Interest Expenses	(\$269)	(\$231)	(\$172)	(\$172)	(\$64)	(\$68)	(\$66)	(\$71)	(\$69)	(\$69)	(\$50)	(\$43)	(\$43)	(\$43)	(\$43)	(\$43)
Interest and other Income, net	\$1,251	\$1,481	\$303	\$376	\$8	\$221	\$396	\$626	\$566	\$771	\$72	\$72	\$79	\$70	\$74	\$80
Others	(\$842)	(\$1,140)	\$0	\$0	\$97	(\$119)	(\$298)	(\$522)	(\$470)	(\$670)	\$0	\$0	\$0	\$0	\$0	\$0
Non-GAAP Pre-tax Income	\$8,702	\$10,906	\$14,989	\$19,595	\$2,231	\$2,214	\$2,277	\$1,980	\$2,134	\$2,568	\$3,019	\$3,185	\$3,290	\$3,574	\$3,897	\$4,228
Provision for Income taxes	\$1,095	\$1,199	\$1,949	\$2,743	\$285	\$274	\$288	\$248	\$235	\$282	\$332	\$350	\$428	\$465	\$507	\$550
Non-GAAP Net Income	\$7,607	\$9,707	\$13,040	\$16,851	\$1,946	\$1,940	\$1,989	\$1,732	\$1,899	\$2,286	\$2,687	\$2,835	\$2,862	\$3,109	\$3,391	\$3,678
GAAP Basic Share Outstanding	803	793	777	760	814	809	798	794	793	794	794	790	785	780	775	770
GAAP Basic EPS	\$8.72	\$13.03	\$16.72	\$22.11	\$1.46	\$2.64	\$2.23	\$2.39	\$2.55	\$3.53	\$3.37	\$3.57	\$3.63	\$3.97	\$4.36	\$4.76
GAAP Diluted Share Outstanding	807	798	782	765	819	812	802	798	799	799	799	795	790	785	780	775
GAAP Diluted EPS	\$8.67	\$12.94	\$16.61	\$21.97	\$1.45	\$2.63	\$2.22	\$2.38	\$2.54	\$3.51	\$3.35	\$3.55	\$3.61	\$3.94	\$4.33	\$4.73
Non-GAAP Diluted EPS	\$9.42	\$12.17	\$16.68	\$22.04	\$2.38	\$2.39	\$2.48	\$2.17	\$2.38	\$2.86	\$3.36	\$3.57	\$3.62	\$3.96	\$4.35	\$4.75
<u>Pro-Forma Reconciliation</u>																
GAAP Gross Profit	\$13,808	\$16,553	\$21,505	\$26,976	\$3,496	\$3,485	\$3,562	\$3,265	\$3,435	\$3,947	\$4,478	\$4,693	\$4,838	\$5,178	\$5,552	\$5,938
Total adjustment	\$27	\$25	\$4	\$4	\$7	\$6	\$7	\$7	\$7	\$6	\$6	\$6	\$1	\$1	\$1	\$1
Non-GAAP Gross Profit	\$13,835	\$16,578	\$21,509	\$26,980	\$3,503	\$3,491	\$3,569	\$3,272	\$3,442	\$3,953	\$4,484	\$4,699	\$4,839	\$5,179	\$5,553	\$5,939
GAAP Operating expenses	\$5,519	\$6,072	\$6,700	\$7,637	\$1,321	\$1,316	\$1,329	\$1,553	\$1,604	\$1,424	\$1,495	\$1,549	\$1,597	\$1,644	\$1,699	\$1,761
Total adjustment	(\$246)	(\$290)	(\$48)	(\$48)	(\$8)	(\$5)	(\$5)	(\$228)	(\$269)	(\$7)	(\$7)	(\$7)	(\$12)	(\$12)	(\$12)	(\$12)
Non-GAAP Operating expenses	\$5,273	\$5,780	\$6,652	\$7,589	\$1,313	\$1,311	\$1,324	\$1,325	\$1,335	\$1,417	\$1,486	\$1,542	\$1,585	\$1,632	\$1,687	\$1,749
GAAP Operating Income	\$8,289	\$10,481	\$14,805	\$19,339	\$2,175	\$2,169	\$2,233	\$1,712	\$1,831	\$2,523	\$2,984	\$3,144	\$3,241	\$3,534	\$3,853	\$4,177
Total adjustment	\$273	\$315	\$52	\$52	\$15	\$11	\$12	\$235	\$276	\$13	\$13	\$13	\$13	\$13	\$13	\$13
Non-GAAP Operating Income	\$8,562	\$10,796	\$14,857	\$19,391	\$2,190	\$2,180	\$2,245	\$1,947	\$2,107	\$2,536	\$2,997	\$3,157	\$3,254	\$3,547	\$3,866	\$4,190
GAAP Provision for income taxes	\$2,273	\$1,403	\$1,949	\$2,743	\$934	\$185	\$784	\$370	\$302	\$419	\$332	\$350	\$428	\$465	\$507	\$550
Total adjustment	(\$1,178)	(\$204)	\$0	\$0	(\$649)	\$89	(\$496)	(\$122)	(\$67)	(\$137)	\$0	\$0	\$0	\$0	\$0	\$0
Non-GAAP adjusted provision for income taxes	\$1,095	\$1,199	\$1,949	\$2,743	\$285	\$274	\$288	\$248	\$235	\$282	\$332	\$350	\$428	\$465	\$507	\$550
GAAP Pre-tax income	\$9,271	\$11,731	\$14,937	\$19,543	\$2,119	\$2,322	\$2,563	\$2,267	\$2,328	\$3,225	\$3,006	\$3,172	\$3,277	\$3,561	\$3,884	\$4,215
Total adjustment	(\$569)	(\$825)	\$52	\$52	\$112	(\$108)	(\$286)	(\$287)	(\$194)	(\$657)	\$13	\$13	\$13	\$13	\$13	\$13
Non-GAAP Pre-tax income	\$8,702	\$10,906	\$14,989	\$19,595	\$2,231	\$2,214	\$2,277	\$1,980	\$2,134	\$2,568	\$3,019	\$3,185	\$3,290	\$3,574	\$3,897	\$4,228
GAAP Net Income	\$6,998	\$10,328	\$12,988	\$16,799	\$1,185	\$2,137	\$1,779	\$1,897	\$2,026	\$2,806	\$2,674	\$2,822	\$2,849	\$3,096	\$3,378	\$3,665
Total adjustment	\$609	(\$621)	\$52	\$52	\$761	(\$197)	\$210	(\$165)	(\$127)	(\$520)	\$13	\$13	\$13	\$13	\$13	\$13
Non-GAAP Net Income	\$7,607	\$9,707	\$13,040	\$16,851	\$1,946	\$1,940	\$1,989	\$1,732	\$1,899	\$2,286	\$2,687	\$2,835	\$2,862	\$3,109	\$3,391	\$3,678
<u>Growth and Margins</u>																
QoQ Revenue Growth					1.7%	(0.9%)	2.8%	(6.9%)	3.1%	12.8%	13.2%	4.6%	2.8%	6.8%	7.0%	6.7%
YoY Revenue Growth	4.4%	17.1%	28.3%	24.5%	6.8%	6.8%	7.7%	(3.5%)	(2.1%)	11.4%	22.6%	37.6%	37.2%	29.9%	22.9%	25.4%
Non-GAAP Gross Margin	48.8%	49.9%	50.5%	50.9%	48.9%	49.2%	48.9%	48.1%	49.1%	50.0%	50.1%	50.2%	50.3%	50.4%	50.5%	50.6%
R&D as % of Sales	12.6%	12.6%	11.6%	10.6%	12.0%	12.6%	12.3%	13.5%	13.2%	13.0%	12.3%	12.3%	12.3%	11.8%	11.4%	11.0%
Marketing as % of Sales	3.0%	2.8%	2.4%	2.2%	2.9%	3.0%	3.1%	3.1%	3.2%	2.9%	2.6%	2.5%	2.5%	2.4%	2.3%	2.3%
G&A as % of Sales	3.2%	2.1%	1.8%	1.6%	3.6%	2.9%	2.8%	3.6%	2.7%	2.1%	1.8%	1.8%	1.8%	1.8%	1.8%	1.7%
Non-GAAP Opex as % of Sales	18.6%	17.4%	15.6%	14.3%	18.3%	18.5%	18.1%	19.5%	19.0%	17.9%	16.6%	16.5%	16.5%	15.9%	15.3%	14.9%
Opex YoY Growth	6.1%	8.8%	15.4%	14.0%	6.7%	6.3%	5.2%	3.9%	1.7%	8.1%	12.2%	16.4%	18.7%	15.2%	13.5%	13.4%
PF Operating Margin	30.2%	32.5%	34.9%	36.5%	30.6%	30.7%	30.7%	28.6%	30.0%	32.1%	33.5%	33.7%	33.8%	34.5%	35.2%	35.7%
Tax Rate	12.6%	11.0%	13.0%	14.0%	12.8%	12.4%	12.6%	12.5%	11.0%	11.0%	11.0%	11.0%	13.0%	13.0%	13.0%	13.0%
Net Margin	26.8%	29.2%	30.6%	31.8%	27.2%	27.3%	27.2%	25.5%	27.1%	28.9%	30.0%	30.3%	29.8%	30.3%	30.8%	31.3%

Source: Company reports, Bernstein estimates and analysis

EXHIBIT 22: Bernstein AMAT Balance Sheet and Cash Flow Statement

BALANCE SHEET																
Fiscal Period	2025	2026E	2027E	2028E	Q125	Q225	Q325	Q425	Q126	Q226	Q326E	Q426E	Q127E	Q227E	Q327E	Q427E
Assets																
Current Assets:																
Cash and cash equivalents	\$7,241.0	\$7,077.0	\$7,938.1	\$11,193.7	\$6,264.0	\$6,169.0	\$5,384.0	\$7,241.0	\$7,218.0	\$6,301.0	\$6,255.0	\$7,077.0	\$6,050.2	\$6,545.3	\$7,253.2	\$7,938.1
Short-term investments	\$1,332.0	\$1,940.0	\$1,940.0	\$1,940.0	\$1,949.0	\$578.0	\$1,630.0	\$1,332.0	\$1,293.0	\$1,940.0	\$1,940.0	\$1,940.0	\$1,940.0	\$1,940.0	\$1,940.0	\$1,940.0
Accounts receivable, net	\$5,185.0	\$6,372.0	\$6,372.0	\$6,372.0	\$5,998.0	\$6,187.0	\$5,772.0	\$5,185.0	\$4,977.0	\$6,372.0	\$6,372.0	\$6,372.0	\$6,372.0	\$6,372.0	\$6,372.0	\$6,372.0
Inventories	\$5,915.0	\$7,171.2	\$8,282.8	\$9,517.6	\$5,501.0	\$5,656.0	\$5,807.0	\$5,915.0	\$5,997.0	\$6,343.0	\$7,116.7	\$7,171.2	\$7,355.4	\$7,560.7	\$7,775.7	\$8,282.8
Other current assets	\$1,208.0	\$1,615.0	\$1,615.0	\$1,615.0	\$982.0	\$1,118.0	\$1,125.0	\$1,208.0	\$1,564.0	\$1,615.0	\$1,615.0	\$1,615.0	\$1,615.0	\$1,615.0	\$1,615.0	\$1,615.0
Total current assets	\$20,881.0	\$24,175.1	\$26,147.9	\$30,638.2	\$20,694.0	\$19,708.0	\$19,718.0	\$20,881.0	\$21,049.0	\$22,571.0	\$23,298.8	\$24,175.1	\$23,332.6	\$24,033.0	\$24,955.9	\$26,147.9
Long-term investments	\$4,327.0	\$5,142.0	\$5,142.0	\$5,142.0	\$2,686.0	\$3,638.0	\$4,133.0	\$4,327.0	\$4,968.0	\$5,142.0	\$5,142.0	\$5,142.0	\$5,142.0	\$5,142.0	\$5,142.0	\$5,142.0
PP&E, net	\$4,610.0	\$5,899.9	\$7,388.7	\$9,235.4	\$3,563.0	\$3,832.0	\$4,124.0	\$4,610.0	\$4,949.0	\$5,255.0	\$5,571.2	\$5,899.9	\$6,233.4	\$6,591.3	\$6,976.3	\$7,388.7
Goodwill	\$3,707.0	\$3,824.0	\$3,824.0	\$3,824.0	\$3,768.0	\$3,748.0	\$3,748.0	\$3,707.0	\$3,707.0	\$3,824.0	\$3,824.0	\$3,824.0	\$3,824.0	\$3,824.0	\$3,824.0	\$3,824.0
Purchased technology and other intangible assets, net	\$226.0	\$310.0	\$270.0	\$230.0	\$237.0	\$249.0	\$238.0	\$226.0	\$215.0	\$330.0	\$320.0	\$310.0	\$300.0	\$290.0	\$280.0	\$270.0
Deferred income taxes and other assets	\$2,548.0	\$3,164.0	\$3,164.0	\$3,164.0	\$2,390.0	\$2,457.0	\$2,250.0	\$2,548.0	\$2,756.0	\$3,164.0	\$3,164.0	\$3,164.0	\$3,164.0	\$3,164.0	\$3,164.0	\$3,164.0
Total assets	\$36,299.0	\$42,515.0	\$45,936.6	\$52,233.6	\$33,338.0	\$33,632.0	\$34,211.0	\$36,299.0	\$37,644.0	\$40,286.0	\$41,319.9	\$42,515.0	\$41,996.0	\$43,044.3	\$44,342.2	\$45,936.6
Liabilities and Stockholders' Equity																
Current liabilities:																
Short-term debt	\$100.0	\$1,199.0	\$0.0	\$0.0	\$799.0	\$799.0	\$799.0	\$100.0	\$100.0	\$1,199.0	\$1,199.0	\$1,199.0	\$0.0	\$0.0	\$0.0	\$0.0
Accounts payable, notes payable and accrued expenses	\$5,333.0	\$5,229.0	\$5,229.0	\$5,229.0	\$4,485.0	\$4,706.0	\$4,614.0	\$5,333.0	\$5,181.0	\$5,229.0	\$5,229.0	\$5,229.0	\$5,229.0	\$5,229.0	\$5,229.0	\$5,229.0
Contract Liabilities	\$2,566.0	\$2,808.0	\$3,521.0	\$4,242.1	\$2,452.0	\$2,491.0	\$2,470.0	\$2,566.0	\$2,472.0	\$2,570.0	\$2,685.2	\$2,808.0	\$2,885.9	\$3,082.5	\$3,298.8	\$3,521.0
Total current liabilities	\$7,999.0	\$9,236.0	\$8,750.0	\$9,471.1	\$7,736.0	\$7,996.0	\$7,883.0	\$7,999.0	\$7,753.0	\$8,998.0	\$9,113.2	\$9,236.0	\$8,114.9	\$8,311.5	\$8,527.8	\$8,750.0
Long-term debt	\$6,455.0	\$5,253.0	\$5,253.0	\$5,253.0	\$5,461.0	\$5,462.0	\$5,463.0	\$6,455.0	\$6,453.0	\$5,256.0	\$5,253.0	\$5,253.0	\$5,253.0	\$5,253.0	\$5,253.0	\$5,253.0
Other liabilities + Income Taxes Payable	\$1,430.0	\$2,123.0	\$2,123.0	\$2,123.0	\$1,516.0	\$1,213.0	\$1,361.0	\$1,430.0	\$1,721.0	\$2,123.0	\$2,123.0	\$2,123.0	\$2,123.0	\$2,123.0	\$2,123.0	\$2,123.0
Total liabilities	\$15,884.0	\$16,612.0	\$16,126.0	\$16,847.1	\$14,713.0	\$14,671.0	\$14,707.0	\$15,884.0	\$15,927.0	\$16,377.0	\$16,489.2	\$16,612.0	\$15,490.9	\$15,687.5	\$15,903.8	\$16,126.0
Total stockholders' equity	\$20,415.0	\$25,903.0	\$29,810.6	\$35,386.5	\$18,625.0	\$18,961.0	\$19,504.0	\$20,415.0	\$21,717.0	\$23,909.0	\$24,830.8	\$25,903.0	\$26,505.1	\$27,356.7	\$28,438.4	\$29,810.6
Total liabilities and stockholders' equity	\$36,299.0	\$42,515.0	\$45,936.6	\$52,233.6	\$33,338.0	\$33,632.0	\$34,211.0	\$36,299.0	\$37,644.0	\$40,286.0	\$41,319.9	\$42,515.0	\$41,996.0	\$43,044.3	\$44,342.2	\$45,936.6
CASH FLOW STATEMENT																
Fiscal Period	2025	2026E	2027E	2028E	Q125	Q225	Q325	Q425	Q126	Q226	Q326E	Q426E	Q127E	Q227E	Q327E	Q427E
Cash flows from operating activities:																
Net income	\$6,998.0	\$10,327.5	\$12,988.0	\$16,799.5	\$1,185.0	\$2,137.0	\$1,779.0	\$1,897.0	\$2,026.0	\$2,806.0	\$2,673.6	\$2,822.0	\$2,849.1	\$3,096.0	\$3,377.7	\$3,665.2
Depreciation and amortization	\$435.0	\$552.7	\$682.5	\$846.0	\$105.0	\$103.0	\$113.0	\$114.0	\$127.0	\$135.0	\$141.4	\$149.3	\$157.5	\$165.8	\$174.8	\$184.4
Share-based compensation	\$668.0	\$714.0	\$676.0	\$676.0	\$195.0	\$159.0	\$158.0	\$156.0	\$207.0	\$169.0	\$169.0	\$169.0	\$169.0	\$169.0	\$169.0	\$169.0
Excess tax benefits from share-based compensation	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
Deferred income taxes	\$639.0	\$74.0	\$0.0	\$0.0	\$668.0	\$4.0	\$280.0	(\$313.0)	(\$78.0)	\$152.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
Other	(\$582.0)	(\$869.0)	\$0.0	\$0.0	\$95.0	(\$109.0)	(\$284.0)	(\$284.0)	(\$202.0)	(\$667.0)	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
Net change in operating assets and liabilities	(\$200.0)	(\$2,734.2)	(\$398.6)	(\$513.7)	(\$1,323.0)	(\$723.0)	\$588.0	\$1,258.0	(\$394.0)	(\$1,750.0)	(\$658.5)	\$68.4	(\$106.3)	(\$8.7)	\$1.2	(\$284.9)
Cash provided by operating activities	\$7,958.0	\$8,065.0	\$13,947.9	\$17,807.9	\$925.0	\$1,571.0	\$2,634.0	\$2,828.0	\$1,686.0	\$845.0	\$2,325.4	\$3,208.6	\$3,069.3	\$3,422.2	\$3,722.7	\$3,733.7
Cash flows from investing activities:																
Capital expenditures	(\$2,260.0)	(\$2,196.5)	(\$2,131.4)	(\$2,652.7)	(\$381.0)	(\$510.0)	(\$584.0)	(\$785.0)	(\$646.0)	(\$635.0)	(\$447.5)	(\$468.0)	(\$481.0)	(\$513.8)	(\$549.8)	(\$586.8)
Cash paid for acquisitions	(\$29.0)	(\$175.0)	\$0.0	\$0.0	(\$28.0)	(\$1.0)	\$0.0	\$0.0	\$0.0	(\$175.0)	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
Proceeds from sale of facility	\$33.0	\$6.0	\$0.0	\$0.0	\$0.0	\$33.0	\$0.0	\$0.0	\$0.0	\$6.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
Proceeds from sales and maturities of investments	\$5,528.0	\$3,234.0	\$0.0	\$0.0	\$1,223.0	\$1,921.0	\$793.0	\$1,591.0	\$1,143.0	\$2,091.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
Purchases of investments	(\$6,054.0)	(\$3,523.0)	\$0.0	\$0.0	(\$1,711.0)	(\$1,222.0)	(\$2,176.0)	(\$945.0)	(\$1,277.0)	(\$2,246.0)	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
Cash used in investing activities	(\$2,782.0)	(\$2,654.5)	(\$2,131.4)	(\$2,652.7)	(\$897.0)	\$221.0	(\$1,967.0)	(\$139.0)	(\$780.0)	(\$959.0)	(\$447.5)	(\$468.0)	(\$481.0)	(\$513.8)	(\$549.8)	(\$586.8)
Cash flows from financing activities:																
Net Change in Debt	\$292.0	(\$103.0)	\$1,199.0	\$0.0	\$0.0	\$0.0	\$0.0	\$292.0	\$0.0	(\$100.0)	(\$3.0)	\$0.0	(\$1,199.0)	\$0.0	\$0.0	\$0.0
Proceeds from common stock issuances	\$261.0	\$131.0	\$0.0	\$0.0	\$0.0	\$129.0	\$0.0	\$132.0	\$0.0	\$131.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
Common stock repurchases	(\$4,895.0)	(\$3,737.0)	(\$8,000.0)	(\$10,000.0)	(\$1,318.0)	(\$1,670.0)	(\$1,056.0)	(\$851.0)	(\$337.0)	(\$400.0)	(\$1,500.0)	(\$1,500.0)	(\$2,000.0)	(\$2,000.0)	(\$2,000.0)	(\$2,000.0)
Excess tax benefits from share-based compensation	(\$248.0)	(\$309.0)	\$0.0	\$0.0	(\$142.0)	(\$35.0)	(\$33.0)	(\$38.0)	(\$229.0)	(\$80.0)	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
Dividends	(\$1,384.0)	(\$1,569.5)	(\$1,756.5)	(\$1,899.6)	(\$326.0)	(\$325.0)	(\$368.0)	(\$365.0)	(\$365.0)	(\$365.0)	(\$420.8)	(\$418.7)	(\$416.1)	(\$413.4)	(\$465.0)	(\$462.0)
Other	(\$3.0)	\$0.0	\$0.0	\$0.0	\$0.0	(\$2.0)	\$0.0	(\$1.0)	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
Cash used in financing activities	(\$5,977.0)	(\$5,587.5)	(\$10,955.5)	(\$11,899.6)	(\$1,786.0)	(\$1,903.0)	(\$1,457.0)	(\$831.0)	(\$931.0)	(\$814.0)	(\$1,923.8)	(\$1,918.7)	(\$3,615.1)	(\$2,413.4)	(\$2,465.0)	(\$2,462.0)
FCF	\$5,698.0	\$5,868.5	\$11,816.5	\$15,155.2	\$544.0	\$1,061.0	\$2,050.0	\$2,043.0	\$1,040.0	\$210.0	\$1,877.9	\$2,740.6	\$2,588.3	\$2,908.4	\$3,172.9	\$3,146.9

Source: Company reports, Bernstein estimates and analysis

EXHIBIT 23: Bernstein LRCX Income Statement

INCOME STATEMENT																				
Fiscal Period	2026	2027E	2028E	2029E	Q126	Q226	Q326	Q426	Q127E	Q227E	Q327E	Q427E	Q128E	Q228E	Q328E	Q428E				
Non-GAAP Revenue	\$23,233	\$34,554	\$38,871	\$45,288	\$5,324	\$5,345	\$5,841	\$6,722	\$8,111	\$8,723	\$8,810	\$8,910	\$9,142	\$9,420	\$9,915	\$10,394				
Non-GAAP COGS	\$11,470	\$16,717	\$18,464	\$21,112	\$2,631	\$2,687	\$2,928	\$3,225	\$3,893	\$4,274	\$4,273	\$4,277	\$4,342	\$4,475	\$4,710	\$4,937				
Non-GAAP Gross Profit	\$11,762	\$17,837	\$20,407	\$24,177	\$2,694	\$2,658	\$2,913	\$3,497	\$4,218	\$4,449	\$4,537	\$4,633	\$4,800	\$4,946	\$5,206	\$5,457				
Non-GAAP Operating Expenses	\$3,442	\$4,327	\$4,759	\$5,148	\$832	\$827	\$866	\$916	\$1,012	\$1,073	\$1,110	\$1,132	\$1,134	\$1,168	\$1,210	\$1,247				
Non-GAAP R&D	\$2,331	\$2,980	\$3,312	\$3,621	\$566	\$565	\$585	\$614	\$688	\$741	\$766	\$784	\$786	\$810	\$843	\$873				
Non-GAAP SG&A	\$1,111	\$1,347	\$1,446	\$1,528	\$266	\$262	\$281	\$302	\$324	\$331	\$344	\$347	\$347	\$358	\$367	\$374				
Non-GAAP Operating Income	\$8,320	\$13,510	\$15,649	\$19,028	\$1,862	\$1,831	\$2,047	\$2,581	\$3,206	\$3,376	\$3,427	\$3,502	\$3,666	\$3,778	\$3,996	\$4,209				
Non-GAAP Other expense, net	(\$9)	\$74	\$220	\$404	\$8	\$10	(\$8)	(\$19)	\$6	\$14	\$20	\$33	\$41	\$50	\$59	\$70				
Non-GAAP Pre-tax Income	\$8,312	\$13,584	\$15,868	\$19,433	\$1,869	\$1,841	\$2,039	\$2,562	\$3,212	\$3,390	\$3,448	\$3,534	\$3,707	\$3,827	\$4,055	\$4,279				
Non-GAAP Provision for Income taxes	(\$978)	(\$2,070)	(\$2,380)	(\$2,915)	(\$265)	(\$244)	(\$188)	(\$282)	(\$514)	(\$509)	(\$517)	(\$530)	(\$556)	(\$574)	(\$608)	(\$642)				
Non-GAAP Net Income	\$7,334	\$11,514	\$13,488	\$16,518	\$1,605	\$1,598	\$1,851	\$2,280	\$2,698	\$2,882	\$2,930	\$3,004	\$3,151	\$3,253	\$3,446	\$3,637				
GAAP Basic Share Outstanding	1,254	1,244	1,225	1,205	1,264	1,255	1,250	1,251	1,250	1,246	1,242	1,238	1,233	1,228	1,223	1,218				
GAAP Basic EPS	\$5.79	\$9.25	\$11.00	\$13.69	\$1.24	\$1.27	\$1.46	\$1.82	\$2.16	\$2.31	\$2.36	\$2.42	\$2.55	\$2.65	\$2.82	\$2.98				
GAAP Diluted Share Outstanding	1,260	1,249	1,230	1,210	1,269	1,262	1,257	1,256	1,255	1,251	1,247	1,243	1,238	1,233	1,228	1,223				
GAAP Diluted EPS	\$5.76	\$9.21	\$10.96	\$13.64	\$1.24	\$1.26	\$1.45	\$1.81	\$2.15	\$2.30	\$2.35	\$2.41	\$2.54	\$2.64	\$2.80	\$2.97				
Non-GAAP Diluted Share Outstanding	1,260	1,249	1,230	1,210	1,269	1,262	1,257	1,256	1,255	1,251	1,247	1,243	1,238	1,233	1,228	1,223				
Non-GAAP Diluted EPS	\$5.82	\$9.22	\$10.97	\$13.65	\$1.26	\$1.27	\$1.47	\$1.82	\$2.15	\$2.30	\$2.35	\$2.42	\$2.55	\$2.64	\$2.81	\$2.98				
Pro-Forma Reconciliation																				
GAAP Revenue	\$23,233	\$34,554	\$38,871	\$45,288	\$5,324	\$5,345	\$5,841	\$6,722	\$8,111	\$8,723	\$8,810	\$8,910	\$9,142	\$9,420	\$9,915	\$10,394				
GAAP COGS	\$11,507	\$16,728	\$18,474	\$21,123	\$2,639	\$2,694	\$2,931	\$3,243	\$3,896	\$4,277	\$4,275	\$4,280	\$4,345	\$4,477	\$4,712	\$4,940				
GAAP Gross Profit	\$11,725	\$17,826	\$20,397	\$24,166	\$2,685	\$2,651	\$2,911	\$3,479	\$4,215	\$4,446	\$4,534	\$4,631	\$4,797	\$4,943	\$5,203	\$5,454				
GAAP R&D	\$2,376	\$2,980	\$3,312	\$3,621	\$576	\$573	\$583	\$643	\$688	\$741	\$766	\$784	\$786	\$810	\$843	\$873				
GAAP SG&A	\$1,150	\$1,348	\$1,448	\$1,529	\$279	\$268	\$280	\$322	\$325	\$332	\$344	\$348	\$348	\$358	\$367	\$375				
GAAP Operating expenses	\$3,526	\$4,328	\$4,760	\$5,150	\$856	\$841	\$864	\$965	\$1,013	\$1,073	\$1,110	\$1,132	\$1,134	\$1,168	\$1,210	\$1,248				
GAAP Operating Income	\$8,200	\$13,498	\$15,637	\$19,016	\$1,829	\$1,810	\$2,047	\$2,513	\$3,203	\$3,373	\$3,424	\$3,499	\$3,663	\$3,775	\$3,993	\$4,206				
GAAP Other expenses, net	\$63	\$72	\$218	\$402	\$30	\$26	(\$35)	\$42	\$6	\$14	\$20	\$32	\$41	\$49	\$58	\$69				
GAAP Pre-tax income	\$8,262	\$13,570	\$15,854	\$19,418	\$1,859	\$1,837	\$2,012	\$2,555	\$3,208	\$3,387	\$3,444	\$3,531	\$3,704	\$3,824	\$4,051	\$4,276				
GAAP Income tax expenses	(\$997)	(\$2,069)	(\$2,380)	(\$2,915)	(\$291)	(\$243)	(\$186)	(\$278)	(\$514)	(\$509)	(\$517)	(\$530)	(\$556)	(\$574)	(\$608)	(\$642)				
GAAP Net Income	\$7,265	\$11,500	\$13,474	\$16,504	\$1,569	\$1,594	\$1,825	\$2,277	\$2,695	\$2,878	\$2,927	\$3,001	\$3,147	\$3,250	\$3,443	\$3,634				
Margins and Growth Rates																				
PF Gross Margins	50.6%	51.6%	52.5%	53.4%	50.6%	49.7%	49.9%	52.0%	52.0%	51.0%	51.5%	52.0%	52.5%	52.5%	52.5%	52.5%				
R&D as % of Sales	10.0%	8.6%	8.5%	8.0%	10.6%	10.6%	10.0%	9.1%	8.5%	8.5%	8.7%	8.8%	8.6%	8.6%	8.5%	8.4%				
SG&A as % of Sales	4.8%	3.9%	3.7%	3.4%	5.0%	4.9%	4.8%	4.5%	4.0%	3.8%	3.9%	3.9%	3.8%	3.8%	3.7%	3.6%				
PF Opex as % of Sales	14.8%	12.5%	12.2%	11.4%	15.6%	15.5%	14.8%	13.6%	12.5%	12.3%	12.6%	12.7%	12.4%	12.4%	12.2%	12.0%				
PF OPM	35.8%	39.1%	40.3%	42.0%	35.0%	34.3%	35.0%	38.4%	39.5%	38.7%	38.9%	39.3%	40.1%	40.1%	40.3%	40.5%				
Tax Rate	(11.8%)	(15.2%)	(15.0%)	(15.0%)	(14.2%)	(13.2%)	(9.2%)	(11.0%)	(16.0%)	(15.0%)	(15.0%)	(15.0%)	(15.0%)	(15.0%)	(15.0%)	(15.0%)				
Net Margin	31.6%	33.3%	34.7%	36.5%	30.1%	29.9%	31.7%	33.9%	33.3%	33.0%	33.3%	33.7%	34.5%	34.5%	34.8%	35.0%				
QoQ																				
Sales					3.0%	0.4%	9.3%	15.1%	20.7%	7.5%	1.0%	1.1%	2.6%	3.0%	5.3%	4.8%				
Gross Profit					3.6%	(1.3%)	9.6%	20.1%	20.6%	5.5%	2.0%	2.1%	3.6%	3.0%	5.3%	4.8%				
R&D					0.1%	(0.0%)	3.6%	4.9%	12.0%	7.8%	3.4%	2.3%	0.3%	3.0%	4.0%	3.6%				
SGA					3.4%	(1.6%)	7.1%	7.6%	7.4%	2.2%	3.7%	1.1%	(0.0%)	3.0%	2.5%	2.0%				
Operating Profit					4.7%	(1.7%)	11.8%	26.1%	24.2%	5.3%	1.5%	2.2%	4.7%	3.0%	5.8%	5.3%				
Tax Rate					-938 bps	93 bps	401 bps	-178 bps	-500 bps	100 bps	00 bps	00 bps	00 bps	00 bps	00 bps	00 bps				
Net Income					(5.5%)	(0.4%)	15.9%	23.1%	18.3%	6.8%	1.7%	2.5%	4.9%	3.2%	5.9%	5.5%				
DSO					(0.6%)	(0.6%)	(0.3%)	(0.1%)	(0.1%)	(0.3%)	(0.3%)	(0.3%)	(0.4%)	(0.4%)	(0.4%)	(0.4%)				
EPS					(4.9%)	0.2%	16.3%	23.3%	18.4%	7.2%	2.0%	2.9%	5.3%	3.7%	6.4%	6.0%				
YoY																				
Sales	26.0%	48.7%	12.5%	16.5%	27.7%	22.1%	23.8%	30.0%	52.3%	63.2%	50.8%	32.5%	12.7%	8.0%	12.5%	16.6%				
Gross Profit	30.7%	51.6%	14.4%	18.5%	34.1%	28.0%	26.0%	34.5%	56.6%	67.4%	55.7%	32.5%	13.8%	11.2%	14.7%	17.8%				
R&D	12.2%	27.9%	11.2%	9.3%	16.1%	14.8%	9.8%	8.8%	21.6%	31.2%	30.9%	27.6%	14.3%	9.3%	10.0%	11.3%				
SGA	15.2%	21.2%	7.4%	5.6%	13.4%	8.3%	21.9%	17.3%	21.8%	26.4%	22.4%	15.0%	7.1%	8.0%	6.8%	7.7%				
Operating Profit	39.7%	62.4%	15.8%	21.6%	44.7%	36.4%	32.1%	45.1%	72.2%	84.4%	67.4%	35.7%	14.4%	11.9%	16.6%	20.2%				
Tax Rate	-93 bps	-347 bps	24 bps	00 bps	-41 bps	-06 bps	412 bps	-622 bps	-184 bps	-177 bps	-578 bps	-400 bps	100 bps	00 bps	00 bps	00 bps				
Net Income	37.6%	57.0%	17.1%	22.5%	43.1%	36.0%	38.6%	34.3%	68.1%	80.4%	58.3%	31.8%	16.8%	12.9%	17.6%	21.1%				
DSO	(2.2%)	(0.9%)	(1.5%)	(1.6%)	(2.7%)	(2.3%)	(2.4%)	(1.6%)	(1.1%)	(0.9%)	(0.8%)	(1.1%)	(1.4%)	(1.4%)	(1.5%)	(1.6%)				
EPS	40.7%	58.5%	18.9%	24.5%	47.0%	39.2%	42.0%	36.5%	70.1%	82.0%	59.6%	33.2%	18.4%	14.6%	19.4%	23.1%				

EXHIBIT 24: Bernstein LRCX Balance Sheet and Cash Flow Statement

BALANCE SHEET																	
Fiscal Period	2026	2027E	2028E	2029E		Q126	Q226	Q326	Q426	Q127E	Q227E	Q327E	Q427E	Q128E	Q228E	Q328E	Q428E
Assets																	
Current Assets:																	
Cash and cash equivalents	\$5,579	\$10,060	\$15,136	\$23,331		\$6,693	\$6,180	\$4,751	\$5,579	\$6,614	\$7,413	\$8,991	\$10,060	\$11,152	\$12,329	\$13,753	\$15,136
Investments	\$0	\$0	\$0	\$0		\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
Accounts receivable, net	\$5,340	\$7,078	\$8,256	\$9,223		\$3,633	\$3,492	\$4,133	\$5,340	\$6,443	\$6,929	\$6,998	\$7,078	\$7,262	\$7,483	\$7,876	\$8,256
Inventories	\$4,276	\$5,560	\$6,171	\$6,676		\$4,095	\$4,038	\$4,000	\$4,276	\$5,256	\$5,642	\$5,341	\$5,560	\$5,645	\$5,817	\$5,887	\$6,171
Prepaid expenses and other current assets	\$416	\$572	\$672	\$751		\$386	\$308	\$413	\$416	\$532	\$558	\$577	\$572	\$593	\$609	\$643	\$672
Non-cash current assets	\$10,032	\$13,210	\$15,099	\$16,650		\$8,114	\$7,838	\$8,546	\$10,032	\$12,231	\$13,129	\$12,916	\$13,210	\$13,500	\$13,909	\$14,406	\$15,099
Total current assets	\$15,611	\$23,270	\$30,236	\$39,981		\$14,807	\$14,018	\$13,297	\$15,611	\$18,845	\$20,542	\$21,907	\$23,270	\$24,652	\$26,238	\$28,159	\$30,236
PP&E, net	\$2,956	\$3,965	\$5,002	\$6,149		\$2,511	\$2,711	\$2,854	\$2,956	\$3,201	\$3,462	\$3,716	\$3,965	\$4,214	\$4,465	\$4,728	\$5,002
Restricted cash and investments	\$0	\$0	\$0	\$0		\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
Goodwill and intangible assets	\$1,896	\$1,884	\$1,872	\$1,860		\$1,827	\$1,864	\$1,882	\$1,896	\$1,893	\$1,890	\$1,887	\$1,884	\$1,881	\$1,878	\$1,875	\$1,872
Other assets	\$3,067	\$4,258	\$4,994	\$5,581		\$2,756	\$2,798	\$2,759	\$3,067	\$3,994	\$4,241	\$4,200	\$4,258	\$4,418	\$4,531	\$4,757	\$4,994
Total assets	\$23,530	\$33,377	\$42,104	\$53,571		\$21,900	\$21,391	\$20,792	\$23,530	\$27,933	\$30,134	\$31,711	\$33,377	\$35,165	\$37,112	\$39,519	\$42,104
Liabilities and Stockholders' Equity																	
Non-debt current liabilities	\$5,933	\$9,799	\$11,430	\$12,769		\$5,954	\$5,459	\$5,238	\$5,933	\$8,916	\$9,593	\$9,690	\$9,799	\$10,053	\$10,360	\$10,904	\$11,430
Current portion of convertible notes and capital leases	\$4	\$4	\$4	\$4		\$754	\$754	\$4	\$4	\$4	\$4	\$4	\$4	\$4	\$4	\$4	\$4
Total current liabilities	\$5,937	\$9,803	\$11,434	\$12,773		\$6,708	\$6,213	\$5,242	\$5,937	\$8,920	\$9,598	\$9,694	\$9,803	\$10,057	\$10,364	\$10,908	\$11,434
Senior notes, convertible notes, and capital leases, less current portion	\$3,730	\$3,730	\$3,730	\$3,730		\$3,730	\$3,730	\$3,730	\$3,730	\$3,730	\$3,730	\$3,730	\$3,730	\$3,730	\$3,730	\$3,730	\$3,730
Income taxes payable	\$681	\$681	\$681	\$681		\$646	\$668	\$622	\$681	\$681	\$681	\$681	\$681	\$681	\$681	\$681	\$681
Other long-term liabilities	\$710	\$951	\$1,108	\$1,200		\$624	\$635	\$613	\$710	\$885	\$973	\$962	\$951	\$980	\$1,007	\$1,057	\$1,108
Total liabilities	\$11,059	\$15,165	\$16,953	\$18,384		\$11,707	\$11,246	\$10,207	\$11,059	\$14,216	\$14,982	\$15,067	\$15,165	\$15,448	\$15,783	\$16,377	\$16,953
Total stockholders' equity	\$12,471	\$18,212	\$25,150	\$35,187		\$10,193	\$10,145	\$10,585	\$12,471	\$13,717	\$15,152	\$16,643	\$18,212	\$19,717	\$21,329	\$23,141	\$25,150
Total liabilities and stockholders' equity	\$23,530	\$33,377	\$42,104	\$53,571		\$21,900	\$21,391	\$20,792	\$23,530	\$27,933	\$30,134	\$31,711	\$33,377	\$35,165	\$37,112	\$39,519	\$42,104
CASH FLOW STATEMENT																	
Fiscal Period	2026	Q209	Q210	Q211		Q126	Q226	Q326	Q426	Q127E	Q227E	Q327E	Q427E	Q128E	Q228E	Q328E	Q428E
Cash flows from operating activities:																	
Net income	\$7,265	\$11,500	\$13,474	\$16,504		\$1,569	\$1,594	\$1,825	\$2,277	\$2,695	\$2,878	\$2,927	\$3,001	\$3,147	\$3,250	\$3,443	\$3,634
Depreciation and amortization	\$442	\$558	\$724	\$903		\$102	\$104	\$116	\$120	\$124	\$134	\$145	\$155	\$165	\$176	\$186	\$197
Other changes to operating cash flows	(\$1,849)	\$221	(\$304)	(\$131)		\$109	(\$218)	(\$800)	(\$940)	\$144	(\$259)	\$462	(\$126)	(\$40)	(\$57)	\$7	(\$215)
Cash provided by operating activities	\$5,858	\$12,279	\$13,894	\$17,275		\$1,779	\$1,480	\$1,141	\$1,457	\$2,962	\$2,753	\$3,535	(\$3,029)	\$3,273	\$3,369	\$3,636	\$3,616
Cash flows from investing activities:																	
Capital expenditures and intangible assets	(\$966)	(\$1,555)	(\$1,749)	(\$2,038)		(\$185)	(\$261)	(\$332)	(\$189)	(\$365)	(\$393)	(\$396)	(\$401)	(\$411)	(\$424)	(\$446)	(\$468)
Business acquisition, net of cash acquired	\$0	\$0	\$0	\$0		\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
Net sales from available-for-sale investments	\$0	\$0	\$0	\$0		\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
Transfers of restricted cash and investments	\$0	\$0	\$0	\$0		\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
Other	\$44	\$0	\$0	\$0		(\$1)	\$3	(\$3)	\$45	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
Cash used in investing activities	(\$922)	(\$1,555)	(\$1,749)	(\$2,038)		(\$186)	(\$258)	(\$335)	(\$144)	(\$365)	(\$393)	(\$396)	(\$401)	(\$411)	(\$424)	(\$446)	(\$468)
Cash flows from financing activities:																	
Debt repayments	(\$755)	\$0	\$0	\$0		(\$1)	(\$1)	(\$751)	(\$1)	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
Debt issuance	\$0	\$0	\$0	\$0		\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
Excess tax benefit on share-based compensation	\$0	\$0	\$0	\$0		\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
Treasury stock purchases	(\$3,851)	(\$4,800)	(\$5,500)	(\$5,500)		(\$976)	(\$1,466)	(\$1,163)	(\$247)	(\$1,200)	(\$1,200)	(\$1,200)	(\$1,200)	(\$1,375)	(\$1,375)	(\$1,375)	(\$1,375)
Dividends paid	(\$1,271)	(\$1,443)	(\$1,569)	(\$1,543)		(\$292)	(\$328)	(\$326)	(\$325)	(\$363)	(\$361)	(\$360)	(\$359)	(\$395)	(\$393)	(\$391)	(\$390)
Reissuance of treasury stock related to employee stock purchase	\$156	\$0	\$0	\$0		\$0	\$67	\$0	\$89	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
Proceeds from issuance of common stock	\$17	\$0	\$0	\$0		\$0	\$4	\$9	\$4	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
Other	(\$14)	\$0	\$0	\$0		(\$12)	(\$1)	\$0	(\$0)	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
Cash used in financing activities	(\$5,718)	(\$6,243)	(\$7,069)	(\$7,043)		(\$1,282)	(\$1,725)	(\$2,231)	(\$480)	(\$1,563)	(\$1,561)	(\$1,560)	(\$1,559)	(\$1,770)	(\$1,768)	(\$1,766)	(\$1,765)
Free Cash Flow	\$4,891	\$10,724	\$12,145	\$15,237		\$1,594	\$1,219	\$810	\$1,268	\$2,597	\$2,361	\$3,138	\$2,629	\$2,861	\$2,945	\$3,190	\$3,148

Source: Company reports, Bernstein estimates and analysis

EXHIBIT 25: KLAC - Income Statement

Income Statement (Non-GAAP), USD in millions except per share																				
Fiscal Period (Fiscal Year ending June 30)					2026	2027E	2028E	2029E	Q126	Q226	Q326	Q426	Q127E	Q227E	Q327E	Q427E	Q128E	Q228E	Q328E	Q428E
Revenue					13,579	18,049	22,173	25,038	3,210	3,297	3,415	3,658	4,000	4,500	4,678	4,871	5,073	5,315	5,759	6,026
COGS					5,106	6,768	8,174	9,139	1,205	1,233	1,291	1,377	1,500	1,687	1,754	1,827	1,877	1,967	2,131	2,199
Gross Profit					8,474	11,281	13,999	15,899	2,005	2,064	2,125	2,281	2,500	2,812	2,924	3,045	3,196	3,349	3,628	3,827
R&D					1,532	1,696	2,040	2,253	360	384	389	399	406	416	430	443	467	489	530	554
SG&A					1,091	1,171	1,375	1,552	258	269	281	283	284	290	295	302	315	330	357	374
Operating Expenses					2,623	2,867	3,415	3,806	618	653	670	682	690	706	725	745	781	819	887	928
Operating Income					5,850	8,414	10,585	12,093	1,386	1,411	1,454	1,599	1,810	2,106	2,199	2,299	2,415	2,530	2,741	2,899
Non-operating Expense / (Income)					(218)	(200)	(218)	(271)	(43)	(38)	(80)	(57)	(45)	(49)	(54)	(52)	(54)	(52)	(54)	(57)
Interest Expense					284	278	278	265	71	70	70	73	69	69	69	69	69	69	69	69
Earnings Before Taxes					5,784	8,336	10,524	12,099	1,359	1,379	1,464	1,582	1,786	2,086	2,183	2,281	2,399	2,513	2,726	2,886
Income Tax Expense / (Benefit)					825	1,209	1,526	1,754	192	211	225	197	259	302	316	331	348	364	395	418
Minority/Non Controlling Interest					-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income					4,959	7,127	8,998	10,344	1,167	1,168	1,239	1,386	1,527	1,783	1,866	1,951	2,051	2,148	2,331	2,468
Basic EPS					\$3.78	\$5.51	\$7.10	\$8.31	\$0.89	\$0.89	\$0.95	\$1.06	\$1.17	\$1.38	\$1.45	\$1.52	\$1.61	\$1.69	\$1.84	\$1.96
Weighted Avg. Shares - Basic (M)					1,311	1,294	1,268	1,245	1,318	1,313	1,309	1,307	1,304	1,297	1,290	1,284	1,277	1,271	1,265	1,259
Diluted EPS					\$3.76	\$5.47	\$7.05	\$8.26	\$0.88	\$0.88	\$0.94	\$1.05	\$1.16	\$1.37	\$1.44	\$1.51	\$1.60	\$1.68	\$1.83	\$1.95
Weighted Avg. Shares - Diluted (M)					1,319	1,302	1,276	1,253	1,324	1,320	1,318	1,315	1,312	1,305	1,298	1,292	1,286	1,279	1,273	1,268
Growth and Margins																				
Revenue QoQ/YoY %					11.7%	32.9%	22.8%	12.9%	1.1%	2.7%	3.6%	7.1%	9.4%	12.5%	4.0%	4.1%	4.1%	4.8%	8.4%	4.6%
Revenue YoY %					11.7%	32.9%	22.8%	12.9%	13.0%	7.2%	11.5%	15.2%	24.6%	36.5%	37.0%	33.2%	26.8%	18.1%	23.1%	23.7%
Gross Margin %					62.4%	62.5%	63.1%	63.5%	62.5%	62.6%	62.2%	62.4%	62.5%	62.5%	62.5%	62.5%	63.0%	63.0%	63.0%	63.5%
Incremental Gross Margin %					63.1%	62.8%	65.9%	66.3%	(8.7%)	67.8%	51.3%	64.4%	64.1%	62.5%	62.5%	62.5%	75.1%	63.0%	63.0%	74.3%
R&D / Sales %					11.3%	9.4%	9.2%	9.0%	11.2%	11.6%	11.4%	10.9%	10.2%	9.3%	9.2%	9.1%	9.2%	9.2%	9.2%	9.2%
SG&A / Sales %					8.0%	6.5%	6.2%	6.2%	8.0%	8.2%	8.2%	7.7%	7.1%	6.5%	6.3%	6.2%	6.2%	6.2%	6.2%	6.2%
Opex/Sales %					19.3%	15.9%	15.4%	15.2%	19.3%	19.8%	19.6%	18.6%	17.3%	15.7%	15.5%	15.3%	15.4%	15.4%	15.4%	15.4%
Operating Margin %					43.1%	46.6%	47.7%	48.3%	43.2%	42.8%	42.6%	43.7%	45.3%	46.8%	47.0%	47.2%	47.6%	47.6%	47.6%	48.1%
Incremental Operating Margin %					42.8%	57.4%	52.6%	52.7%	(52.5%)	28.5%	36.7%	59.4%	61.7%	59.2%	52.1%	52.0%	57.3%	47.6%	47.6%	58.9%
Tax Rate %					14.3%	14.5%	14.5%	14.5%	14.1%	15.3%	15.4%	12.4%	14.5%	14.5%	14.5%	14.5%	14.5%	14.5%	14.5%	14.5%
Net Margin %					36.5%	39.5%	40.6%	41.3%	36.4%	35.4%	36.3%	37.9%	38.2%	39.6%	39.9%	40.0%	40.4%	40.4%	40.5%	40.9%
Diluted EPS QoQ/YoY %					13.0%	45.6%	28.8%	17.1%	(6.0%)	0.4%	6.2%	12.1%	10.4%	17.4%	5.2%	5.0%	5.7%	5.2%	9.0%	6.3%
Diluted EPS YoY %					13.0%	45.6%	28.8%	17.1%	20.3%	7.9%	11.8%	12.4%	32.0%	54.4%	52.9%	43.2%	37.1%	22.9%	27.4%	29.0%

Source: Company reports, Bernstein estimates and analysis

EXHIBIT 26: **KLAC - Balance Sheet**

GLOBAL SEMICONDUCTOR CAPITAL EQUIPMENT

Balance Sheet, USD in millions																
Fiscal Period (Fiscal Year ending June 30)	2026E	2027E	2028E	2029E	Q126	Q226	Q326	Q426	Q127E	Q227E	Q327E	Q427E	Q128E	Q228E	Q328E	Q428E
Cash and Equivalents & Marketable Securities	4,902	7,199	8,493	10,644	4,684	5,207	4,958	4,902	6,690	6,887	6,868	7,199	6,955	7,251	7,604	8,493
Accounts Receivable	2,889	3,248	4,017	4,140	2,278	2,074	2,304	2,889	2,889	3,000	3,119	3,248	3,382	3,543	3,839	4,017
Inventories	3,649	4,466	5,377	5,541	3,297	3,283	3,437	3,649	3,833	4,125	4,288	4,466	4,588	4,807	5,209	5,377
Other Current Assets	942	967	1,196	1,233	642	700	652	942	794	893	929	967	1,007	1,055	1,143	1,196
Total Current Assets	12,382	15,880	19,084	21,558	10,901	11,264	11,351	12,382	14,206	14,906	15,204	15,880	15,932	16,657	17,795	19,084
Property Plant & Equipment, Net	1,381	1,629	1,946	2,281	1,302	1,345	1,364	1,381	1,432	1,495	1,561	1,629	1,699	1,774	1,858	1,946
Deferred Tax Assets	1,037	1,381	1,709	1,761	1,131	1,144	1,123	1,037	1,410	1,561	1,539	1,381	1,788	1,844	1,894	1,709
Purchased Intangible Assets, net	256	127	78	42	397	348	301	256	224	191	159	127	114	102	90	78
Goodwill	1,789	1,789	1,789	1,789	1,791	1,791	1,788	1,789	1,789	1,789	1,789	1,789	1,789	1,789	1,789	1,789
Other Noncurrent Assets	1,107	1,138	1,408	1,451	795	829	946	1,107	935	1,052	1,093	1,138	1,186	1,242	1,346	1,408
Total Assets	17,952	21,944	26,013	28,882	16,318	16,720	16,874	17,952	19,994	20,994	21,344	21,944	22,508	23,408	24,772	26,013
Accounts Payable	624	710	855	881	430	425	515	624	667	750	682	710	730	765	829	855
Current Portion of Long-Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue (systems+services)	1,537	2,524	3,122	3,217	1,424	1,457	1,197	1,537	2,072	2,331	2,423	2,524	2,628	2,754	2,984	3,122
Other Current Liabilities	2,144	3,343	4,135	4,261	2,197	2,100	2,039	2,144	2,745	3,088	3,210	3,343	3,481	3,647	3,952	4,135
Total Current Liabilities	4,305	6,577	8,112	8,360	4,050	3,982	3,752	4,305	5,483	6,169	6,316	6,577	6,839	7,166	7,764	8,112
Long Term Debt	5,887	5,887	5,887	5,087	5,885	5,886	5,887	5,887	5,887	5,887	5,887	5,887	5,887	5,887	5,887	5,887
Deferred Income Taxes (Liabilities)	474	533	539	432	465	453	444	474	499	528	515	533	531	517	519	539
Deferred Revenue (Long-Term, Service)	238	390	482	497	287	271	252	238	320	360	374	390	406	425	461	482
Other Noncurrent Liabilities	698	1,012	1,252	1,290	646	663	709	698	831	935	972	1,012	1,054	1,104	1,196	1,252
Total Liabilities	11,602	14,399	16,273	15,665	11,333	11,254	11,043	11,602	13,021	13,879	14,064	14,399	14,717	15,099	15,827	16,273
Non Controlling Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Common Stock and capital in excess of par value	2,700	2,700	2,700	2,700	2,489	2,604	2,675	2,700	2,700	2,700	2,700	2,700	2,700	2,700	2,700	2,700
Accumulated Other Comprehensive Income	(34)	(34)	(34)	(34)	1	1	(32)	(34)	(34)	(34)	(34)	(34)	(34)	(34)	(34)	(34)
Retained Earnings	3,684	4,878	7,074	10,550	2,495	2,861	3,187	3,684	4,307	4,449	4,614	4,878	5,125	5,643	6,279	7,074
Total Equity	6,350	7,544	9,740	13,216	4,985	5,466	5,830	6,350	6,973	7,115	7,280	7,544	7,791	8,309	8,945	9,740
Total Liabilities and Shareholders Equity	17,952	21,944	26,013	28,882	16,318	16,720	16,874	17,952	19,994	20,994	21,344	21,944	22,508	23,408	24,772	26,013
Summary metrics																
EBITDA	6,244	8,836	10,982	12,545	1,483	1,510	1,554	1,697	1,911	2,210	2,306	2,410	2,508	2,627	2,842	3,004
LTM EBITDA	6,244	8,836	10,982	12,545	5,843	5,947	6,048	6,244	6,672	7,372	8,124	8,836	9,433	9,851	10,388	10,982
Net Debt	985	(1,312)	(2,606)	(5,557)	1,202	679	929	985	(802)	(1,000)	(981)	(1,312)	(1,068)	(1,364)	(1,716)	(2,606)
Leverage (Net Debt/EBITDA)	0.2x	(0.1x)	(0.2x)	(0.4x)	0.2x	0.1x	0.2x	0.2x	(0.1x)	(0.1x)	(0.1x)	(0.1x)	(0.1x)	(0.1x)	(0.2x)	(0.2x)
Invested Capital / Net Operating Assets	6,606	6,204	7,008	7,825	6,187	6,144	6,760	7,335	6,171	6,115	6,299	6,232	6,723	6,945	7,229	7,134
NOPAT	5,059	7,194	9,050	10,340	1,265	1,121	1,276	1,398	1,547	1,801	1,880	1,966	2,065	2,163	2,344	2,478
ROIC (annualized)	77%	116%	129%	132%	82%	73%	76%	76%	100%	118%	119%	126%	123%	125%	130%	139%

Source: Company reports, Bernstein estimates and analysis

David Dai, CFA +852 2918 5704 david.dai@bernsteinsg.com

11 August 2026

EXHIBIT 27: KLAC - Cash Flow Statement

Cash Flow Statement, USD in millions																	
Fiscal Period (Fiscal Year ending June 30)	2026E	2027E	2028E	2029E	Q126	Q226	Q326	Q426	Q127E	Q227E	Q327E	Q427E	Q128E	Q228E	Q328E	Q428E	
Net income (GAAP)	4,831	7,053	8,975	10,327	1,121	1,146	1,201	1,363	1,499	1,768	1,851	1,935	2,045	2,142	2,325	2,462	
Depreciation and Amortization	394	422	397	451	97	99	99	99	101	104	107	110	94	97	101	105	
Unrealized foreign exchange loss and other	7	-	-	-	12	2	(14)	6	-	-	-	-	-	-	-	-	
Stock-based compensation	310	413	507	571	70	74	84	82	87	101	115	109	111	119	142	135	
Deferred income taxes	78	(284)	(322)	(160)	(11)	(32)	15	105	(347)	(123)	10	176	(409)	(71)	(49)	206	
Goodwill and other impairment charges	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Other operating cash flow	(1)	-	-	-	-	-	(1)	-	-	-	-	-	-	-	-	-	
Accounts receivable	(642)	(358)	(770)	(123)	(13)	191	(234)	(586)	0	(111)	(119)	(129)	(134)	(161)	(296)	(178)	
Inventories	(466)	(817)	(911)	(164)	(96)	1	(159)	(212)	(185)	(292)	(163)	(178)	(123)	(219)	(402)	(168)	
Other assets	(501)	(57)	(499)	(79)	51	(65)	(64)	(423)	320	(216)	(77)	(84)	(87)	(105)	(192)	(115)	
Accounts payable	172	87	145	26	(24)	(5)	93	108	43	83	(68)	28	20	35	64	27	
Deferred system revenue	116	633	384	61	2	39	(237)	312	343	166	59	64	67	81	148	89	
Deferred service revenue	(55)	505	306	49	(5)	(22)	(42)	14	274	133	47	51	53	64	118	71	
Other liabilities	(100)	1,513	1,032	164	(44)	(61)	(34)	39	734	447	159	173	180	217	397	239	
Cash Flow from operating activities	4,143	9,109	9,245	11,124	1,162	1,368	707	906	2,870	2,060	1,921	2,257	1,818	2,199	2,356	2,872	
Capital expenditures	(376)	(541)	(665)	(751)	(96)	(106)	(85)	(89)	(120)	(135)	(140)	(146)	(152)	(159)	(173)	(181)	
Net Proceeds from sale of assets / businesses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Business acquisitions, net of cash acquired	17	-	-	-	2	15	-	-	-	-	-	-	-	-	-	-	
Net purchases of securities	(833)	-	-	-	(316)	(22)	(412)	(84)	-	-	-	-	-	-	-	-	
Net proceeds from other investments	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Other investing cash flow	2	-	-	-	-	-	2	-	-	-	-	-	-	-	-	-	
Cash Flow from investing activities	(1,190)	(541)	(665)	(751)	(410)	(113)	(494)	(173)	(120)	(135)	(140)	(146)	(152)	(159)	(173)	(181)	
Common stock repurchases	(2,290)	(5,100)	(6,000)	(6,000)	(545)	(548)	(626)	(571)	(600)	(1,500)	(1,500)	(1,500)	(1,500)	(1,500)	(1,500)	(1,500)	
Issuance of common stock	169	226	276	299	-	56	0	113	-	76	0	151	-	90	0	186	
Tax withholding payments related to vested and released RSUs	(205)	(167)	(210)	(236)	(81)	(6)	(4)	(114)	(63)	(5)	(4)	(95)	(81)	(6)	(5)	(119)	
Dividend to stockholders	(1,058)	(1,231)	(1,351)	(1,486)	(254)	(250)	(249)	(305)	(300)	(298)	(297)	(336)	(329)	(327)	(326)	(369)	
Proceeds from debt issuance, net of issuance costs	(2)	-	-	-	(2)	-	-	-	-	-	-	-	-	-	-	-	
Repayment of debt	-	-	-	(800)	-	-	-	-	-	-	-	-	-	-	-	-	
Other financing cash flow	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Cash Flow from financing activities	(3,386)	(6,271)	(7,286)	(8,222)	(882)	(748)	(879)	(877)	(963)	(1,727)	(1,800)	(1,780)	(1,910)	(1,744)	(1,830)	(1,802)	
Effect of exchange rate changes on cash and cash equivalents	4	-	-	-	(3)	(1)	1	7	-	-	-	-	-	-	-	-	
Net increase (decrease) in cash and cash equivalents	(429)	2,297	1,294	2,151	(133)	506	(665)	(137)	1,787	198	(19)	331	(244)	296	353	890	
Cash and cash equivalents at beginning of period	2,079	1,650	3,947	5,241	2,079	1,946	2,452	1,787	1,650	3,437	3,635	3,616	3,947	3,702	3,999	4,351	
Cash and cash equivalents at end of period	1,650	3,947	5,241	7,392	1,946	2,452	1,787	1,650	3,437	3,635	3,616	3,947	3,702	3,999	4,351	5,241	
Summary metrics																	
FCF (\$M)	3,767	8,568	8,580	10,373	1,066	1,262	622	817	2,750	1,925	1,781	2,111	1,665	2,040	2,183	2,691	
FCF margin (% sales)	27.7%	47.5%	38.7%	41.4%	33.2%	38.3%	18.2%	22.3%	68.8%	42.8%	38.1%	43.3%	32.8%	38.4%	37.9%	44.7%	
FCF conversion (% PF net income)	76.0%	120.2%	95.3%	100.3%	91.3%	108.0%	50.2%	59.0%	180.1%	107.9%	95.4%	108.2%	81.2%	94.9%	93.7%	109.1%	
Capex intensity (% sales)	(2.8%)	(3.0%)	(3.0%)	(3.0%)	(3.0%)	(3.2%)	(2.5%)	(2.4%)	(3.0%)	(3.0%)	(3.0%)	(3.0%)	(3.0%)	(3.0%)	(3.0%)	(3.0%)	
Dividends (% FCF)	28.1%	14.4%	15.7%	14.3%	23.8%	19.8%	40.0%	37.4%	10.9%	15.5%	16.7%	15.9%	19.8%	16.1%	14.9%	13.7%	
Share repurchases (% FCF)	60.8%	59.5%	69.9%	57.8%	51.1%	43.4%	100.6%	69.9%	21.8%	77.9%	84.2%	71.0%	90.1%	73.5%	68.7%	55.7%	
Capital returns (% FCF)	88.9%	73.9%	85.7%	72.2%	75.0%	63.2%	140.6%	107.2%	32.7%	93.4%	100.9%	87.0%	109.8%	89.6%	83.6%	69.4%	

Source: Company reports, Bernstein estimates and analysis

DISCLOSURE APPENDIX

I. REQUIRED DISCLOSURES

References to "Bernstein" or the "Firm" in these disclosures relate to the following entities: Bernstein Institutional Services LLC (April 1, 2024 onwards), Sanford C. Bernstein & Co., LLC (pre April 1, 2024), Bernstein Autonomous LLP, BSG France S.A. (April 1, 2024 onwards), Sanford C. Bernstein (Hong Kong) Limited 盛博香港有限公司, Sanford C. Bernstein (Canada) Limited, Sanford C. Bernstein (India) Private Limited (SEBI registration no. INH000006378), Sanford C. Bernstein (Singapore) Private Limited, Sanford C. Bernstein Japan KK (サンフォード・C・バーンスタイン株式会社) and analysts employed by Société Générale Africa Technologies & Services to produce Bernstein research under a Global Services Agreement in place between Bernstein and Société Générale.

Bernstein is part of a joint venture between Société Générale (SG) and AllianceBernstein, L.P. (AB). Unless specifically noted otherwise, for purposes of these disclosures, references to Bernstein's "affiliates" relate to both SG and AB and their respective affiliates.

VALUATION METHODOLOGY

This research publication covers six or more companies. For valuation methodology and other company disclosures:

Please visit: <https://bernstein-autonomous.bluematrix.com/sellside/Disclosures.action>.

Or, you can also write to the Director of Compliance, Bernstein Institutional Services LLC, 245 Park Avenue, New York, NY 10167.

RISKS

This research publication covers six or more companies. For risks and other company disclosures:

Please visit: <https://bernstein-autonomous.bluematrix.com/sellside/Disclosures.action>.

Or, you can also write to the Director of Compliance, Bernstein Institutional Services LLC, 245 Park Avenue, New York, NY 10167.

RATINGS DEFINITIONS, BENCHMARKS AND DISTRIBUTION**EQUITY RATINGS DEFINITIONS****Bernstein brand**

The Bernstein brand rates stocks based on forecasts of relative performance for the next 12 months versus the S&P 500 for stocks listed on the U.S. and Canadian exchanges, versus the Bloomberg Europe Developed Markets Large and Mid Cap Price Return Index EUR (EDME) for stocks listed on the European exchanges and emerging markets exchanges outside of the Asia Pacific region, versus the Bloomberg Japan Large and Mid Cap Price Return Index USD (JPL) for stocks listed on the Japanese exchanges, and versus the Bloomberg Asia ex-Japan Large and Mid Cap Price Return Index (ASIA) for stocks listed on the Asian (ex-Japan) exchanges -unless otherwise specified.

The Bernstein brand has three categories of ratings:

- Outperform: Stock will outpace the market index by more than 15 pp
- Market-Perform: Stock will perform in line with the market index to within +/- 15 pp
- Underperform: Stock will trail the performance of the market index by more than 15 pp

Coverage Suspended: Coverage of a company under the Bernstein research brand has been suspended. Ratings and price targets are suspended temporarily, are no longer current, and should therefore not be relied upon.

Not Rated: A rating assigned when the stock cannot be accurately valued, or the performance of the company accurately predicted, at the present time. The covering analyst may continue to publish research reports on the company to update investors on events and developments.

Not Covered (NC) denotes companies that are not under coverage.

Bernstein brand stock ratings are based on a 12-month time horizon.

Autonomous brand – common stocks

The Autonomous brand rates common stocks as indicated below. As our benchmarks we use the Bloomberg Europe 600 Financials Price Return Index (E600BK) and Bloomberg Europe Dev Mkt Financials Large and Mid Cap Price Ret Index EUR (EDMFI) index for developed European banks and Payments, the Bloomberg Europe 600 Insurance Price Return Index (E600IN) for European insurers, the S&P 500 and S&P Financials for US banks and Payments coverage, S5LIFE for US Insurance, the S&P Insurance Select Industry (SPSIINS) for US Non-Life Insurers coverage, the Bloomberg Emerging Markets Financials Large, Mid and Small Cap Price Return Index (EMLSF) for emerging market banks and insurers and Payments, and the Bloomberg Japan Financials Large & Mid Cap Price Return Index (JPFILM) for Japanese Financials. Ratings are stated relative to the sector (not the market).

The Autonomous brand has three categories of common stock ratings:

- Outperform (OP): Stock will outpace the relevant index by more than 10 pp
- Neutral (N): Stock will perform in line with the market index to within +/-10 pp
- Underperform (UP): Stock will trail the performance of the relevant index by more than 10 pp

Coverage Suspended: Coverage of a company under the Autonomous research brand has been suspended. Ratings and price targets are suspended temporarily, are no longer current, and should therefore not be relied upon.

Not Rated: A rating assigned when the stock cannot be accurately valued, or the performance of the company accurately predicted, at the present time. The covering analyst may continue to publish research reports on the company to update investors on events and developments.

Those denoted as 'Feature' (e.g., Feature Outperform FOP, Feature Under Outperform FUP) are our core ideas.

Not Covered (NC) denotes companies that are not under coverage.

Autonomous brand common stock ratings are based on a 12-month time horizon.

Autonomous brand – preferred stocks

The Autonomous brand has three categories of preferred stock ratings:

- Outperform (OP): The total return of the preferred instrument is expected to outperform preferred securities of other issuers operating in similar sectors or rating categories over the next six months.
- Neutral (N): The total return of the preferred instrument is expected to perform in line with preferred securities of other issuers operating in similar sectors or rating categories over the next six months.
- Underperform (UP): The total return of the preferred instrument is expected to underperform preferred securities of other issuers operating in similar sectors or rating categories over the next six months.

Autonomous preferred stock ratings are based on a 6-month time horizon.

AUTONOMOUS CREDIT RESEARCH


Where this report contains investment recommendations for credit instruments, as defined in article 3(1)(35) of the Market Abuse Regulation, the information below is presented to comply with its disclosure requirements.

The report may also include reference(s) to published opinions by other Autonomous or Bernstein analysts covering the equity securities of the issuer(s) referenced herein. Please note an investment recommendation for credit instruments published by the author(s) of this report may differ from the published view of the analyst covering equity securities for the issuer(s) contained in this report and vice versa.

CREDIT RATINGS DEFINITIONS

The Autonomous brand has three categories of credit ratings:

- Credit Outperform (C-OP): The total return of the Reference Credit Instrument is expected to outperform the bonds of other issuers operating in similar sectors or rating categories over the next six months.



- **Credit Neutral (C-N):** The total return of the Reference Credit Instrument is expected to perform in line with the credit spread of bonds of other issuers operating in similar sectors or rating categories over the next six months.
- **Credit Underperform (C-UP):** The total return of the Reference Credit Instrument is expected to underperform the credit spread of bonds of other issuers operating in similar sectors or rating categories over the next six months.

Autonomous credit ratings are based on a 6-month time horizon.

A list of all investment recommendations produced by the author(s) of this report alongside credit ratings history are available upon request.

It is at the sole discretion of the Firm as to when to initiate, update and cease research coverage. The Firm has established, maintains and relies on information barriers to control the flow of information contained in one or more areas (i.e. the private side) within the Firm, and into other areas, units, groups or affiliates (i.e. public side) of the Firm

DISTRIBUTION OF EQUITY RATINGS/INVESTMENT BANKING SERVICES

Equity Rating	Market Abuse Regulation (MAR) and FINRA Rating Category	Global Rating Distribution	Investment Banking Relationships*
Outperform	BUY	51.2%	15.3%
Market-Perform (Bernstein Brand) Neutral (Autonomous Brand)	HOLD	35.8%	16.2%
Underperform	SELL	13.1%	13.6%

* These figures represent the percentage of companies within each equity rating category for which affiliates of Bernstein have provided investment banking services within the previous 12 months.

As of June 30, 2026. All figures are updated quarterly.

Prior to April 1, 2024, Sanford C. Bernstein & Co., LLC. issued the ratings and price target information in the graph(s) below for the following companies: Applied Materials Inc and Lam Research Corp.

PRICE CHARTS/ RATINGS AND PRICE TARGET HISTORY

This research publication covers six or more companies. For price chart and other company disclosures, please visit <https://bernstein-autonomous.bluematrix.com/sellside/Disclosures.action> or you can write to the Director of Compliance, Bernstein Institutional Services LLC, 245 Park Avenue, New York, NY 10167.

CONFLICTS OF INTEREST

All statements in this report attributable to Gartner represent Bernstein's interpretation of data, research opinion or viewpoints published as part of a syndicated subscription service by Gartner, Inc., and have not been reviewed by Gartner. Each Gartner publication speaks as of its original publication date (and not as of the date of this report). The opinions expressed in Gartner publications are not representations of fact, and are subject to change without notice.

Stacy A. Rasgon maintains long positions in various crypto currencies.

SG and/or its affiliates beneficially own 0.5% or more of [the total issued share capital/any class of common equity securities] with a net [long/short] position of: Kokusai Electric Corp.

SG and/or its affiliates beneficially own 1% or more of a class of common equity securities of the following company: Kokusai Electric Corp.

Bernstein Autonomous LLP or BSG France SA, beneficially, has either a net long or short position of 0.5% or more of the total issued share capital of a class of common equity securities of the following MiFID eligible securities: Applied Materials Inc and KLA Corporation.

Bernstein and/or affiliates have received compensation for non-investment banking securities-related products or services in the previous twelve months from the following clients: Screen Holdings Co Ltd.

Bernstein and/or affiliates expect to receive or intend to seek compensation for investment banking services in the next three months from Tokyo Electron Ltd.

Bernstein and/or affiliates had an investment banking client relationship during the past twelve months with Tokyo Electron Ltd.

Certain affiliates of Bernstein act as market maker or liquidity provider in the debt securities of: Screen Holdings Co Ltd, Applied Materials Inc and ASML Holding NV.

Certain affiliates of Bernstein act as market maker or liquidity provider in the equities securities of: Applied Materials Inc, Lam Research Corp and ASML Holding NV.

OTHER MATTERS

The legal entity(ies) employing the analyst(s) listed in this report, and their location, can be determined by the country code of their phone number, as follows:

- +1 Bernstein Institutional Services LLC; New York, New York, USA
- +44 Bernstein Autonomous LLP; London UK
- +212 Société Générale Africa Technologies & Services; Casablanca, Morocco
- +33 BSG France S.A.; Paris, France
- +34 BSG France S.A.; Madrid, Spain
- +41 Bernstein Autonomous LLP; Geneva, Switzerland
- +49 BSG France S.A.; Frankfurt, Germany
- +91 Sanford C. Bernstein (India) Private Limited; Mumbai, India
- +852 Sanford C. Bernstein (Hong Kong) Limited 盛博香港有限公司; Hong Kong, China
- +65 Sanford C. Bernstein (Singapore) Private Limited; Singapore
- +81 Sanford C. Bernstein Japan KK; Tokyo, Japan

Where this report has been prepared by research analyst(s) employed by a non-US affiliate, such analyst(s), is/are (unless otherwise expressly noted below) not registered as associated persons of Bernstein Institutional Services LLC or any other SEC-registered broker-dealer and are not licensed or qualified as research analysts with FINRA. Accordingly, such analyst(s) may not be subject to FINRA's restrictions regarding (among other things) communications by research analysts with a subject company, interactions between research analysts and investment banking personnel, participation by research analysts in solicitation and marketing activities relating to investment banking transactions, public appearances by research analysts, and trading securities held by a research analyst account.

Where this report has been prepared by research analyst(s) employed by Société Générale Africa Technologies & Services (part of the Société Générale group of companies), it has been prepared on behalf of a Bernstein company under a Global Services Agreement in place between Bernstein and Société Générale.

CERTIFICATION

Each research analyst listed in this report, who is primarily responsible for the preparation of the content of this report, certifies that all of the views expressed in this publication accurately reflect that analyst's personal views about any and all of the subject securities or issuers and that no part of that analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views in this publication.

II. ADDITIONAL GLOBAL CONFLICT DISCLOSURES

It is at the sole discretion of the Firm as to when to initiate, update and cease research coverage. The Firm has established, maintains and relies on information barriers to control the flow of information contained in one or more areas (i.e., the private side) within the Firm, and into other areas, units, groups or affiliates (i.e., public side) of the Firm.

III. OTHER IMPORTANT INFORMATION AND DISCLOSURES

Separate branding is maintained for “Bernstein” and “Autonomous” research products.

- Bernstein produces a number of different types of research products including, among others, fundamental analysis and quantitative analysis under both the “Autonomous” and “Bernstein” brands. Recommendations contained within one type of research product may differ from recommendations contained within other types of research products, whether as a result of differing time horizons, methodologies or otherwise. Furthermore, views or recommendations within a research product issued under one brand may differ from views or recommendations under the same type of research product issued under the other brand. The Research Ratings System for the two brands and other information related to those Rating Systems are included in the previous section.
- Autonomous operates as a separate business unit within the following entities: Bernstein Institutional Services LLC, Bernstein Autonomous LLP, Sanford C. Bernstein (Hong Kong) Limited 盛博香港有限公司 and Sanford C. Bernstein (India) Private Limited. For information relating to “Autonomous” branded products (including certain Sales materials) please visit: www.autonomous.com. For information relating to Bernstein branded products please visit: www.bernsteinresearch.com.

Analysts are compensated based on aggregate contributions to the research franchise as measured by account penetration, productivity and proactivity of investment ideas. No analysts are compensated based on performance in, or contributions to, generating investment banking revenues.

This report has been produced by an independent analyst as defined in Article 3 (1)(34)(i) of EU 596/2014 Market Abuse Regulation (“MAR”) and the same article of MAR as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018.

To our readers in the United States: Bernstein Institutional Services LLC, a broker-dealer registered with the U.S. Securities and Exchange Commission (“SEC”) and a member of the U.S. Financial Industry Regulatory Authority, Inc. (“FINRA”) is distributing this publication in the United States and accepts responsibility for its contents. Where this material contains an analysis of debt product(s), such material is intended only for institutional investors and is not subject to the US independence and disclosure standards applicable to debt research prepared for retail investors.

Bernstein Institutional Services LLC may act as principal for its own account or as agent for another person (including an affiliate) in sales or purchases of any security which is a subject of this report. This report does not purport to meet the objectives or needs of any specific individuals, entities or accounts.

To our readers in Canada: If this publication pertains to a Canadian domiciled company, it is being distributed in Canada by Sanford C. Bernstein (Canada) Limited, which is licensed and regulated by the Canadian Investment Regulatory Organization. If the publication pertains to a non-Canadian domiciled company, it is being distributed by Bernstein Institutional Services LLC, which is licensed and regulated by both the SEC and FINRA, into Canada under the International Dealers Exemption.

This document may not be passed onto any person in Canada unless that person qualifies as “permitted client” as defined in Section 1.1 of NI 31-103.

To our readers in Brazil: This report has been prepared by Bernstein Institutional Services LLC, and Banco BTG Pactual S.A. (“BTG”) is responsible for the distribution of this report in Brazil.

To readers in the United Kingdom: This publication has been issued or approved for issue in the United Kingdom by Bernstein Autonomous LLP, authorised and regulated by the Financial Conduct Authority and located at 60 London Wall, London EC2M 5SH, +44 (0)20-7170-5000. Registered in England & Wales No OC343985.

This document is for distribution only to persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the “Financial Promotion Order”), (ii) are persons falling within Article 49(2)(a) to (d) (“high net worth companies, unincorporated associations, etc.”) of the Financial Promotion Order, (iii) are outside the United Kingdom, or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the FSMA) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as “relevant persons”). This document is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this document relates is available only to relevant persons and will be

engaged in only with relevant persons.

To our readers in the member states of the EEA: This publication is being distributed by BSG France SA, which is authorised and regulated by the Autorité de Contrôle Prudentiel et de Résolution (ACPR) and Autorité des Marchés Financiers (AMF).

To our readers in Hong Kong: This publication is being distributed in Hong Kong by Sanford C. Bernstein (Hong Kong) Limited 盛博香港有限公司, which is licensed and regulated by the Hong Kong Securities and Futures Commission (Central Entity No. AXC846) to carry out Type 4 (Advising on Securities) regulated activities and subject to the licensing conditions mentioned in the SFC Public Register (<https://www.sfc.hk/publicregWeb/corp/AXC846/details>). This publication is solely for professional investors, as defined in the Securities and Futures Ordinance (Cap. 571). The purpose of this report is solely to provide an analysis of the issuers referred to in this report and is not intended for any purpose contrary to the laws of Hong Kong.

To our readers in Singapore: This publication is being distributed in Singapore by Sanford C. Bernstein (Singapore) Private Limited, only to accredited investors or institutional investors, as defined in the Securities and Futures Act 2001 of Singapore ("SFA"). Recipients in Singapore should contact Sanford C. Bernstein (Singapore) Private Limited in respect of matters arising from, or in connection with, this publication. Sanford C. Bernstein (Singapore) Private Limited is regulated by the Monetary Authority of Singapore and licensed under the SFA as a capital markets services licence holder for dealing in capital markets products that are securities and collective investment schemes and an exempt financial adviser for advising on, issuing and promulgating analyses and reports on securities. Sanford C. Bernstein (Singapore) Private Limited is registered in Singapore with Company Registration No. 20213710W and located at 8 Marina Boulevard, #12-01, Marina Bay Financial Centre, Singapore 018981, +65-6326-7000.

To our readers in the People's Republic of China: The securities referred to in this document are not being offered or sold and may not be offered or sold, directly or indirectly, in the People's Republic of China (for such purposes, not including the Hong Kong and Macau Special Administrative Regions or Taiwan, the "PRC") in contravention of any applicable laws of the PRC.

This document does not constitute an offer to sell or the solicitation of an offer to buy any securities in the PRC to any person to whom it is unlawful to make the offer or solicitation in the PRC.

We do not represent that this document may be lawfully distributed, or that any securities may be lawfully offered, in compliance with any applicable registration or other requirements in the PRC, or pursuant to an exemption available thereunder, or assume any responsibility for facilitating any such distribution or offering. In particular, no action has been taken by us which would permit a public offering of any securities or distribution of this document in the PRC. Accordingly, the securities are not being offered or sold within the PRC by means of this document or any other document. Neither this document nor any advertisement or other offering material may be distributed or published in the PRC, except under circumstances that will result in compliance with any applicable laws and regulations.

To our readers in Japan: This publication is being distributed in Japan by Sanford C. Bernstein Japan KK (サンフォード・C・バーンスタイン株式会社), which is registered in Japan as a Financial Instruments Business Operator with the Kanto Local Finance Bureau (registration number: The Director-General of Kanto Local Finance Bureau (FIBO) No.3387) and regulated by the Financial Services Agency. It is also a member of Investment Management Association of Japan. This publication is solely for qualified institutional investors in Japan only, as defined in Article 2, paragraph (3), items (i) of the Financial Instruments and Exchange Act.

For the institutional client readers in Japan who have been granted access to the Bernstein website by Daiwa Securities Group Inc. ("Daiwa"), your access to this document should not be construed as meaning that Bernstein is providing you with investment advice for any purposes. Whilst Bernstein has prepared this document, your relationship is, and will remain with, Daiwa, and Bernstein has neither any contractual relationship with you nor any obligations towards you.

To our readers in Australia: Sanford C. Bernstein (Hong Kong) Limited 盛博香港有限公司 is responsible for distributing research in Australia. It is regulated by the Securities and Exchange Commission under U.S. laws, by the Financial Conduct Authority under U.K. laws, which differs from Australian laws. Sanford C. Bernstein (Hong Kong) Limited 盛博香港有限公司 is exempt from the requirement to hold an Australian financial services license under the Corporations Act 2001 in respect of the provision of the following financial services to wholesale clients:

- providing financial product advice;
- dealing in a financial product;
- making a market for a financial product; and
- providing a custodial or depository service.

To our readers in India: This publication is being distributed in India by Sanford C. Bernstein (India) Private Limited (SCB India) which is licensed and regulated by Securities and Exchange Board of India ("SEBI") as a research analyst entity under the SEBI (Research Analyst) Regulations, 2014, having registration no. INH000006378 and as a stock broker having registration no. INZ000213537. SCB India is currently engaged in the business of providing research and stock broking services. Please refer to www.bernsteinresearch.in for more information.

- SCB India is a Private limited company incorporated under the Companies Act, 2013, on April 12, 2017 bearing corporate identification number U65999MH2017FTC293762, and registered office at Level 3A, 4th Floor, First International Financial Centre, Plot Nos C-54 and C-55, G Block, Near CBI Office, Bandra Kurla Complex, Bandra (East), Mumbai 400098, Maharashtra, India (Phone No: +91-22-68421401).
- For details of Associates (i.e., affiliates/group companies) of SCB India, kindly email MUM-BERNSTEIN-InCompliance@bernsteinsg.com.
- SCB India does not have any disciplinary history as on the date of this report.
- Except as noted above, SCB India and/or its Associates (i.e., affiliates/group companies), the Research Analysts authoring this report, and their relatives
 - do not have any financial interest in the subject company
 - do not have actual/beneficial ownership of one percent or more in securities of the subject company;
 - is not engaged in any investment banking activities for Indian companies, as such;
 - have not managed or co-managed a public offering in the past twelve months for any Indian companies;
 - have not received any compensation for investment banking services or merchant banking services from the subject company in the past 12 months;
 - have not received compensation for brokerage services from the subject company in the past twelve months;
 - have not received any compensation or other benefits from the subject company or third party related to the specific recommendations or views in this report; and
 - do not currently, but may in the future, act as a market maker in the financial instruments of the companies covered in the report.
 - do not have any conflict of interest in the subject company as of the date of this report.
- Except as noted above, the subject company has not been a client of SCB India during twelve months preceding the date of distribution of this research report. Neither SCB India nor its Associates (i.e., affiliates/group companies) have received compensation for products or services other than investment banking, merchant banking or brokerage services from the subject company in the past twelve months.
- The principal research analyst(s) who prepared this report, members of the analysts' team, and members of their households are not an officer, director, employee or advisory board member of the companies covered in the report.
- Our Compliance officer / Grievance officer is Ms. Rupal Talati, who can be reached at +91-22-68421451, or MUM-BERNSTEIN-InCompliance@bernsteinsg.com / Scbin-investorgrievance@bernsteinsg.com
- The Research investor charter and Terms & Conditions of SCB India are available on its website and may be accessed at [Sanford C. Bernstein \(India\) Private Limited](http://SanfordC.Bernstein(India)PrivateLimited) (<https://bernsteinresearch.in/>) for your reference.
- Disclaimer: Registration granted by SEBI, and certification from NISM, is in no way a guarantee of performance of the intermediary or provide any assurance of returns to investors. Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

To our readers in Switzerland: This document is provided in Switzerland by or through Bernstein Autonomous LLP, and is provided only to qualified investors as defined in article 10 of the Swiss Collective Investment Scheme Act ("CISA") and related

provisions of the Collective Investment Scheme Ordinance and in strict compliance with applicable Swiss law and regulations. The products mentioned in this document may not be suitable for all types of investors. This document is based on the Directives on the Independence of Financial Research issued by the Swiss Bankers Association (SBA) in January 2008.

To our readers in the Middle East: Bernstein Autonomous LLP, DIFC branch has its principal office at Gate Village 06, DIFC, Dubai, UAE. Bernstein Autonomous LLP, DIFC branch is regulated by the Dubai Financial Services Authority (DFSA) with the registration number CL10040 and is provisioned for Arranging Deals in Investments and Advising on Financial Products. All communications and services are directed at Professional Clients and Market Counterparties only (as defined in the DFSA rulebook). Persons other than Professional Clients and Market Counterparties, such as Retail Clients, are not the intended recipients of our communications or services.

LEGAL

All research publications are disseminated to our clients through posting on the firm's password protected websites, bernsteinresearch.com and autonomous.com. Certain, but not all, research publications are also made available to clients through third-party vendors or redistributed to clients through alternate electronic means as a convenience.

This publication has been published and distributed in accordance with the Firm's policy for management of conflicts of interest in investment research, a copy of which is available from Bernstein Institutional Services LLC, Director of Compliance, 245 Park Avenue, New York, NY 10167. Additional disclosures and information regarding Bernstein's business are available on our website www.bernsteinresearch.com.

The securities described herein may not be eligible for sale in all jurisdictions or to certain categories of investors where that permission profile is not consistent with the licenses held by the entities noted herein. This document is for distribution only as may be permitted by law. This publication is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of, or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject any of the entities referenced herein or any of their subsidiaries or affiliates to any registration or licensing requirement within such jurisdiction. This publication is based upon public sources we believe to be reliable, but no representation is made by us that the publication is accurate or complete. We do not undertake to advise you of any change in the reported information or in the opinions herein. This publication was prepared and issued by entity referred to herein for distribution to eligible counterparties or professional clients. This publication is not an offer to buy or sell any security, and it does not constitute investment, legal or tax advice. The investments referred to herein may not be suitable for you. Investors must make their own investment decisions in consultation with their professional advisors in light of their specific circumstances. The value of investments may fluctuate, and investments that are denominated in foreign currencies may fluctuate in value as a result of exposure to exchange rate movements. Information about past performance of an investment is not necessarily a guide to, indicator of, or assurance of, future performance.

This report is directed to and intended only for our clients who are "eligible counterparties", "professional clients", "institutional investors" and/or "professional investors" as defined by the aforementioned regulators, and must not be redistributed to retail clients as defined by the aforementioned regulators. Retail clients who receive this report should note that the services of the entities noted herein are not available to them and should not rely on the material herein to make an investment decision. The result of such act will not hold the entities noted herein liable for any loss thus incurred as the entities noted herein are not registered/ authorised/ licensed to deal with retail clients and will not enter into any contractual agreement/arrangement with retail clients. This report is provided subject to the terms and conditions of any agreement that the clients may have entered into with the entities noted herein. All research reports are disseminated on a simultaneous basis to eligible clients through electronic publication to our client portal.

The information in this report was prepared by Bernstein solely for the internal business use of our clients. Clients may store, display, analyze, reformat and print the information in this report for this limited use only. Clients may not copy, alter, create derivative works, resell, reverse engineer, commercially exploit, share or distribute any part of the information contained herein for any purpose without Bernstein's express written consent. These restrictions include extracting data or using the content to develop indices or other products. Further, you may not use this report, or any portion of this report, to train or finetune any third-party machine learning or artificial intelligence system, or as a prompt or input into any such system. You also may not, without Bernstein's express written consent, do any of the foregoing in connection with your own internal machine learning or artificial intelligence system.

Bernstein may use artificial intelligence tools in the preparation of its materials. Any such materials are reviewed by Bernstein's research analysts prior to publication.

This report has been prepared for information purposes only and is based on current public information that we consider reliable, but the entities noted herein do not warrant or represent (express or implied) as to the sources of information or data contained herein are accurate, complete, not misleading or as to its fitness for the purpose intended even though the entities noted herein rely on reputable or trustworthy data providers, it should not be relied upon as such. Opinions expressed are the author(s)' current

opinions as of the date appearing on the material only and we do not undertake to advise you of any change in the reported information or in the opinions herein.

Any references to Societe Generale herein are purely factual, based upon publicly available information, and included for comparative purposes only. They do not constitute an opinion or recommendation with respect to the securities of Societe Generale.

This publication was prepared and issued by the entity referred to herein for distribution to eligible counterparties or professional clients. The information in this report is intended for general circulation and does not constitute an offer to buy or sell any security, investment, legal or tax advice nor a personal recommendation, as defined by any of the aforementioned regulators. It does not take into account the particular investment objectives, financial situations, or needs of individual investors. The report has not been reviewed by any of the aforementioned regulators and does not represent any official recommendation from the aforementioned regulators. The investments referred to herein may not be suitable for you. Investors must make their own investment decisions in consultation with advice sought from a financial adviser regarding the suitability of the investment product, taking into account the specific investment objectives, financial situation or particular needs of any recipient of the recommendation, before the recipient makes a commitment to purchase the investment product.

The analysis contained herein is based on numerous assumptions. Different assumptions could result in materially different results. The information in this report does not constitute, or form part of, any offer to sell or issue, or any offer to purchase or subscribe for shares, or to induce engagement in any other investment activity. The value of any securities or financial instruments mentioned in this report may fluctuate subject to market conditions. Information about past performance of an investment is not necessarily a guide to, indicative of, or assurance of future performance. Estimates of future performance mentioned by the research analyst in this report are based on assumptions that may not be realized due to unforeseen factors like market volatility/fluctuation. In relation to securities or financial instruments denominated in a foreign currency other than the clients' home currency, movements in exchange rates will have an effect on the value, either favorable or unfavorable. Before acting on any recommendations in this report, recipients should consider the appropriateness of investing in the subject securities or financial instruments mentioned in this report and, if necessary, seek independent professional advice.

The securities described herein may not be eligible for sale in all jurisdictions or to certain categories of investors where that permission profile is not consistent with the licenses held by the entities noted herein. This document is for distribution only as may be permitted by law. It is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or would subject the entities noted herein to any regulation or licensing requirement within such jurisdiction.

Source: Bloomberg Index Services Limited. BLOOMBERG® is a trademark and service mark of Bloomberg Finance L.P. and its affiliates (collectively "Bloomberg"). Bloomberg or Bloomberg's licensors own all proprietary rights in the Bloomberg Indices. Neither Bloomberg nor Bloomberg's licensors approves or endorses this material, or guarantees the accuracy or completeness of any information herein, or makes any warranty, express or implied, as to the results to be obtained therefrom and, to the maximum extent allowed by law, neither shall have any liability or responsibility for injury or damages arising in connection therewith.

No part of this material may be reproduced, distributed or transmitted or otherwise made available without prior consent of the entities noted herein. Copyright Bernstein Institutional Services LLC Bernstein Autonomous LLP, BSG France S.A., Sanford C. Bernstein (Hong Kong) Limited 盛博香港有限公司, Sanford C. Bernstein (Canada) Limited, Sanford C. Bernstein (India) Private Limited (SEBI registration no. INH000006378), Sanford C. Bernstein (Singapore) Private Limited and Sanford C. Bernstein Japan KK (サンフォード・C・バーンスタイン株式会社). All rights reserved. The trademarks and service marks contained herein are the property of their respective owners. Any unauthorized use or disclosure is strictly prohibited. The entities noted herein may pursue legal action if the unauthorized use results in any defamation and/or reputational risk to the entities noted herein and research published under the Bernstein and Autonomous brands.